Primary Site >> Colorectal Cancer
Gene >> EGFR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Amplification and elevated expression of c-myc in a chemically induced mouse colon tumor. PMID: 4028026 |
Ref: Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. PMID: 2887281 |
Ref: Ras gene activation and epidermal growth factor receptor expression in human colon cancer. PMID: 2682005 |
Ref: Expression of several growth factors and their receptor genes in human colon carcinomas. PMID: 1980764 Ref: erbB-2 gene expression in colorectal cancer. PMID: 1982887 Ref: Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. PMID: 2106751 Ref: Growth factors and oncogenes in human gastrointestinal carcinomas. PMID: 2157713 Ref: Epidermal growth factor receptors in colorectal carcinoma. PMID: 2195985 Ref: Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha. PMID: 2250044 Ref: Growth stimulation by coexpression of transforming growth factor-alpha and epidermal growth factor-receptor in normal and adenomatous human colon epithelium. PMID: 2365825 |
Ref: Differential expression of epidermal growth factor-related proteins in human colorectal tumors. PMID: 1715580 Ref: [Immunohistochemical study on the expression of epidermal growth factor receptor (EGFR) in human colorectal carcinomas]. PMID: 1880949 Ref: Receptors for epidermal growth factor and steroid hormones in primary colorectal tumors. PMID: 1943115 Ref: Extrachromosomal amplification of the epidermal growth factor receptor gene in a human colon carcinoma cell line. PMID: 2069908 Ref: The proliferative and morphologic responses of a colon carcinoma cell line (LIM 1215) require the production of two autocrine factors. PMID: 2072905 |
Ref: Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. PMID: 1285215 Ref: Colorectum cell-derived growth factor (CRDGF) is homologous to amphiregulin, a member of the epidermal growth factor family. PMID: 1333777 Ref: [Expression of c-erbB-2 protein and vessel invasion in colorectal cancer]. PMID: 1346087 Ref: Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer. PMID: 1419612 Ref: Differential regulation of transforming growth factor alpha autoinduction in a nontransformed and transformed epithelial cell. PMID: 1419897 Ref: Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. PMID: 1434639 Ref: [Complex characteristics of the alterations of oncogenes HER-2/ERBB-2, HER-1/ERBB-1, HRAS-1, C-MYC and antioncogenes p53, RB1, as well as deletions of loci of chromosome 17 in colon carcinoma]. PMID: 1470178 Ref: Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody. PMID: 1732118 Ref: Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue. PMID: 1739615 Ref: Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. PMID: 1741162 |
Ref: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. PMID: 7688814 Ref: Study of c-erbB-2 protein and epidermal growth factor receptor expression and DNA ploidy pattern in colorectal carcinoma. PMID: 7902886 Ref: [Immunohistochemical study of the coexpression of epidermal growth factor receptor (EGFR) and c-erbB-2 protein in colorectal cancer]. PMID: 7903710 Ref: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. PMID: 8095852 Ref: Epidermal growth factor, transforming growth factor-alpha, and epidermal growth factor receptor content in normal and carcinomatous gastric and colonic tissue. PMID: 8312682 Ref: A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. PMID: 8439966 Ref: Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene. PMID: 8453634 Ref: Growth control in a human colon carcinoma cell line mediated by cell-associated transforming growth factor-alpha (TGF alpha). PMID: 8482359 Ref: In situ evaluation of the relationship between epidermal-growth-factor-receptor status and tumor-cell proliferation in colon carcinomas. PMID: 8486422 Ref: [Immunohistochemical studies on expression of epidermal growth factor receptor (EGFR) and proliferative activity in human colorectal cancers]. PMID: 8509061 |
Ref: Serum levels of c-erbB-2 protein in digestive diseases. PMID: 7528080 Ref: Esophageal cancer. PMID: 7533069 Ref: Accelerated growth of human colon cancer cells in nude mice undergoing liver regeneration. PMID: 7657529 Ref: Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. PMID: 7868086 Ref: Expression of EGF, EGF-receptor, p53, v-erb B and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues. PMID: 7912978 Ref: Demonstration of epidermal growth factor receptor in colorectal adenocarcinoma by enzyme immunoassay. PMID: 8187972 Ref: Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. PMID: 8306274 Ref: Expression of cripto-1 in human colorectal adenomas and carcinomas is related to the degree of dysplasia. PMID: 21559596 |
Ref: Epidermal growth factor expression in human colon and colon carcinomas: anti-sense epidermal growth factor receptor RNA down-regulates the proliferation of human colon cancer cells. PMID: 7558411 Ref: PSA immunoreactivity detected in LNCaP cell medium, breast tumor cytosol, and female serum. PMID: 7562242 Ref: Expression of antisense epidermal growth factor receptor RNA downmodulates the malignant behavior of human colon cancer cells. PMID: 7750206 Ref: Expression of epidermal growth factor receptor messenger RNA in human colorectal carcinomas assessed by non-radioactive in-situ hybridization. PMID: 7781795 Ref: Regulation of autocrine gastrin expression by the TGF alpha autocrine loop. PMID: 7822434 Ref: Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease. PMID: 7895532 Ref: Expression of growth factors and their receptors in human early colorectal carcinomas: immunohistochemical study. PMID: 8669884 Ref: Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. PMID: 9815969 |
Ref: p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles. PMID: 8556707 Ref: Autocrine growth stimulation of SW403 colon carcinoma cell line is caused by transforming-growth-factor-alpha-mediated epidermal growth factor receptor activation. PMID: 8642042 Ref: Raf-1 kinase, epidermal growth factor receptors, and mutant Ras proteins in colonic carcinomas. PMID: 8654136 Ref: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. PMID: 8944008 Ref: Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolypoid and polypoid lesions of the colon. PMID: 21544470 |
Ref: Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. PMID: 9012840 Ref: Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners. PMID: 9046331 Ref: Expression of growth factor receptors is not a prognostic indicator in young patients with colorectal cancer. PMID: 9114679 Ref: The epidermal growth factor receptor is involved in autocrine growth of human bladder carcinoma cell lines. PMID: 9216646 Ref: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. PMID: 9354447 Ref: ErbB kinases and NDF signaling in human prostate cancer cells. PMID: 9400997 Ref: Clinical experience with CD64-directed immunotherapy. An overview. PMID: 9435876 Ref: Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. PMID: 9444956 |
Ref: Molecular changes during the genesis of human gliomas. PMID: 9407626 Ref: Distinctive karyotypes and growth patterns in nude mice reveal cross-contamination in an established human cancer cell line. PMID: 9458333 Ref: Expression of TGFalpha autocrine activity in human colon carcinoma CBS cells is autoregulated and independent of exogenous epidermal growth factor. PMID: 9525476 Ref: Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. PMID: 9558281 Ref: Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. PMID: 9563874 Ref: Epidermal growth factor receptor expression in primary cultured human colorectal carcinoma cells. PMID: 9667648 Ref: EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. PMID: 9677101 Ref: Enhanced ligand-induced activation of EGF-receptor and overall tyrosine kinase and phospholipase C in colonocytes isolated from azoxymethane-treated rats. PMID: 9684124 Ref: Inhibition of human colon cancer malignant cell behavior and growth by antisense epidermal growth factor receptor expression vector. PMID: 9703869 Ref: Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. PMID: 9712416 Ref: A comparative study of nucleolar organizer region, proliferating cell nuclear antigen and epidermal growth factor receptor staining in colon tumours. PMID: 9736172 Ref: [Dysfunction of E-cadherin-catenin system in invasion and metastasis of colorectal cancer]. PMID: 9742518 Ref: Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. PMID: 9747879 Ref: Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. PMID: 9755233 Ref: Serum obtained from rats after partial hepatectomy enhances growth of cultured colon carcinoma cells. PMID: 10474028 Ref: [Multivariate analysis of clinicopathological and immunohistochemical factors in colorectal carcinomas]. PMID: 11244942 |
Ref: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. PMID: 10213228 Ref: Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. PMID: 10362109 Ref: Role of epidermal growth factor receptor in basal and stimulated colonic epithelial cell migration in vitro. PMID: 10388532 Ref: Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. PMID: 10425310 Ref: Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices. PMID: 10470163 Ref: Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: relevance for suppression of epidermal growth factor-stimulated cell growth. PMID: 10489163 Ref: Folic acid inhibition of EGFR-mediated proliferation in human colon cancer cell lines. PMID: 10600765 Ref: Induction of epidermal growth factor receptor expression and mitogenesis by alcohol in human colon adenocarcinoma-derived Caco-2 cells. PMID: 10652628 Ref: Prognostic evaluation of metallothionein expression in human colorectal neoplasms. PMID: 10711249 |
Ref: Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. PMID: 10686540 Ref: Vitamin D receptor gene BsmI polymorphism correlates with erbB-2/HER-2 expression in human rectal cancer. PMID: 10765127 Ref: Defective cleavage of membrane bound TGFalpha leads to enhanced activation of the EGF receptor in malignant cells. PMID: 10773880 Ref: Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. PMID: 10778975 Ref: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. PMID: 10815932 Ref: Microgravity culture reduces apoptosis and increases the differentiation of a human colorectal carcinoma cell line. PMID: 10949995 Ref: Electrocautery snare resection stimulates cellular proliferation of residual colorectal tumor: an increasing gene expression related to tumor growth. PMID: 10950009 Ref: Different expression of some molecular markers in sporadic cancer of the left and right colon. PMID: 10958329 Ref: Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. PMID: 10974196 Ref: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. PMID: 10999768 Ref: c-erbB-2 protein expression and clinicopathologic features in colorectal cancer. PMID: 11032920 Ref: Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. PMID: 11073812 Ref: Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. PMID: 11106252 Ref: The coordinated functional expression of epidermal growth factor receptor and c-Met in colorectal carcinoma metastasis. PMID: 11125542 Ref: Gastrointestinal tract antigenic profile of cotton-top tamarin, Saguinus oedipus, is similar to that of humans with inflammatory bowel disease. PMID: 11258547 Ref: C-erbB-2 oncoprotein content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance. PMID: 11729856 Ref: [Comparative study of metastasis-associated characteristics of tumor cells with different metastatic capacities]. PMID: 11778231 Ref: Inhibitory effects of EGFR antisense oligodeox ynucleotide in human colorectal cancer cell line. PMID: 11819687 |
Ref: Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR. PMID: 11287320 Ref: Construction of tumor-specific cells expressing a membrane-anchored single-chain Fv of anti-ErbB-2 antibody. PMID: 11342269 Ref: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. PMID: 11375952 Ref: [The role of estrogen receptor, vitamin D receptor and calcium receptor genotypes in the pathogenesis of colorectal cancer]. PMID: 11392075 Ref: Increased in vitro activation of EGFR by membrane-bound TGF-alpha from gastric and colonic mucosa of aged rats. PMID: 11408261 Ref: Transforming growth factor-alpha prevents detachment-induced inhibition of c-Src kinase activity, Bcl-XL down-regulation, and apoptosis of intestinal epithelial cells. PMID: 11487584 Ref: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. PMID: 11506500 Ref: Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers. PMID: 11506951 Ref: Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. PMID: 11562278 Ref: Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. PMID: 11571982 Ref: EGFR and cancer prognosis. PMID: 11597399 Ref: The EGFR as a target for anticancer therapy--focus on cetuximab. PMID: 11597400 Ref: Upregulation of non-mutated H-ras and its upstream and downstream signaling proteins in colorectal cancer. PMID: 11605075 Ref: Microsatellite instability, PTEN and p53 germline mutations in glioma families. PMID: 11669337 |
Ref: Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands. PMID: 11684674 Ref: Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. PMID: 11818567 Ref: c-erbB-2 is not a major factor in the development of colorectal cancer. PMID: 11870539 Ref: Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. PMID: 11875501 Ref: Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. PMID: 11891209 Ref: [Clinical assessment of monoclonal antibodies for the treatment and diagnosis of colorectal cancers]. PMID: 11904970 Ref: [Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors]. PMID: 11904986 Ref: Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. PMID: 11910351 Ref: Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. PMID: 11973637 Ref: Systemic treatment of colorectal cancer. PMID: 11978525 Ref: Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). PMID: 11986789 Ref: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. PMID: 12006511 Ref: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. PMID: 12008194 Ref: Calcium-sensing receptor A986S polymorphism in human rectal cancer. PMID: 12018449 Ref: Current concepts in immunotherapy for the treatment of colorectal cancer. PMID: 12018689 Ref: The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. PMID: 12053861 Ref: A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. PMID: 12067982 Ref: [Central role of epidermic growth factor receptor (EGFR) in hypertrophic gastropathy and cancer of the colon]. PMID: 12193872 Ref: Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. PMID: 12198768 Ref: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). PMID: 12374696 Ref: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. PMID: 12409327 Ref: Therapeutics targeting signal transduction for patients with colorectal carcinoma. PMID: 12421735 Ref: The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. PMID: 12422306 Ref: Epidermal growth factor receptor-targeted therapy in colorectal cancer. PMID: 12422309 Ref: Epidermal growth factor receptor expression and measurement in solid tumors. PMID: 12422313 Ref: Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. PMID: 12422314 Ref: The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). PMID: 12429914 Ref: Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. PMID: 12441262 Ref: Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. PMID: 12459370 Ref: Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. PMID: 12480194 Ref: Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. PMID: 12507930 Ref: Epithelial growth factor receptor interacting agents. PMID: 12512382 Ref: Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase-overexpressing human colon carcinoma cells. PMID: 12664617 |
Ref: Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. PMID: 12469172 Ref: Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR. PMID: 12527944 Ref: Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. PMID: 12569594 Ref: Epidermal growth factor receptor as a therapeutic target in colorectal cancer. PMID: 12620146 Ref: Investigations for a multi-marker RT-PCR to improve sensitivity of disseminated tumor cell detection. PMID: 12680210 Ref: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. PMID: 12684431 Ref: Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. PMID: 12684433 Ref: Redifferentiation and ZO-1 reexpression in liver-metastasized colorectal cancer: possible association with epidermal growth factor receptor-induced tyrosine phosphorylation of ZO-1. PMID: 12708492 Ref: Epidermal growth factor receptor-related protein: a potential therapeutic agent for colorectal cancer. PMID: 12730874 Ref: Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells. PMID: 12748850 Ref: Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. PMID: 12790326 Ref: Development of ZD1839 in colorectal cancer. PMID: 12802791 Ref: Signaling inhibition with radiation in colorectal cancer: clinical trials. PMID: 12802796 Ref: Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. PMID: 12810453 Ref: [Chemoprevention: treatment of persons at high risk of cancer]. PMID: 12822011 Ref: Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. PMID: 12824187 Ref: [Overexpression of c-erbB-2 and hypoexpression of nm23 relating to poor prognosis of colorectal carcinoma]. PMID: 12839671 Ref: A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. PMID: 12855618 Ref: Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. PMID: 12855647 Ref: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. PMID: 12860957 Ref: Molecular modes of action of artesunate in tumor cell lines. PMID: 12869643 Ref: Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells. PMID: 12881705 Ref: Gastrin and EGF synergistically induce cyclooxygenase-2 expression in Swiss 3T3 fibroblasts that express the CCK2 receptor. PMID: 12891702 Ref: Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. PMID: 12906920 Ref: The role of transforming growth factor alpha in determining growth factor independence. PMID: 12907656 Ref: New targeted therapies in gastrointestinal cancers. PMID: 12941199 Ref: Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. PMID: 12958170 Ref: Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels. PMID: 14530681 Ref: [Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy]. PMID: 14579760 Ref: Transactivation of the epidermal growth factor receptor mediates cholinergic agonist-induced proliferation of H508 human colon cancer cells. PMID: 14583469 Ref: Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. PMID: 14623871 Ref: [Novel molecular approaches in the therapy of advanced colorectal carcinoma]. PMID: 14716146 Ref: Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. PMID: 14752222 Ref: [Studies on cancer chemoprevention by tea pigments]. PMID: 14963910 Ref: Monoclonal antibodies in human cancer. PMID: 14988743 Ref: The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. PMID: 14988746 Ref: New oxaliplatin-based combinations in the treatment of colorectal cancer. PMID: 23573555 |
Ref: Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. PMID: 14569062 Ref: Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. PMID: 14648715 Ref: Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha. PMID: 14684586 Ref: HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. PMID: 14696118 Ref: The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. PMID: 14719098 Ref: Cetuximab: in the treatment of metastatic colorectal cancer. PMID: 14723561 Ref: Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. PMID: 14742435 Ref: Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. PMID: 14747693 Ref: Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. PMID: 14750183 Ref: Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. PMID: 14760092 Ref: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. PMID: 14760102 Ref: Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. PMID: 14993229 Ref: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. PMID: 14993230 Ref: Folic acid reduces nuclear translocation of beta-catenin in rectal mucosal crypts of patients with colorectal adenomas. PMID: 15019156 Ref: Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. PMID: 15059917 Ref: Folic acid-mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. PMID: 15075253 Ref: Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes. PMID: 15077188 Ref: Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors. PMID: 15108418 Ref: Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled? PMID: 15134356 Ref: Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. PMID: 15142629 Ref: Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. PMID: 15143334 Ref: The ErbB/HER receptor protein-tyrosine kinases and cancer. PMID: 15158434 Ref: Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. PMID: 15161648 Ref: The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). PMID: 15183125 Ref: Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. PMID: 15207021 Ref: Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. PMID: 15210862 Ref: Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. PMID: 15228443 Ref: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. PMID: 15269313 Ref: Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. PMID: 15294912 Ref: Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. PMID: 15300804 Ref: Autocrine transforming growth factor alpha regulates cell adhesion by multiple signaling via specific phosphorylation sites of p70S6 kinase in colon cancer cells. PMID: 15304500 Ref: Integration of novel agents in the treatment of colorectal cancer. PMID: 15309512 Ref: Expression of epidermal growth factor-receptor related protein (ERRP) in human colorectal carcinogenesis. PMID: 15327841 Ref: Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. PMID: 15332713 Ref: Chemopreventive role of folic acid in colorectal cancer. PMID: 15353309 Ref: Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. PMID: 15383630 Ref: A review of oxaliplatin and its clinical use in colorectal cancer. PMID: 15461551 Ref: EGFR-targeted therapy for patients with colorectal cancer: patient management and future directions. PMID: 15478587 Ref: Transactivation of E-cadherin is not involved in the activity of EGF receptor in colorectal carcinoma cells. PMID: 15492839 Ref: EGF-receptor related protein causes cell cycle arrest and induces apoptosis of colon cancer cells in vitro and in vivo. PMID: 15517892 Ref: Age-related loss of EGF-receptor related protein (ERRP) in the aging colon is a potential risk factor for colon cancer. PMID: 15563939 Ref: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. PMID: 15570078 Ref: An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. PMID: 15604284 Ref: Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. PMID: 15634648 Ref: Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells. PMID: 15634655 Ref: Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. PMID: 15638954 Ref: Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. PMID: 15638959 Ref: Epidermal growth factor receptor inhibitors and colorectal cancer. PMID: 15685832 Ref: [Antibodies against cancer]. PMID: 15710074 Ref: Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition. PMID: 19780248 Ref: (99m)Tc-Cys-Gly-Gly-Affibody ZHER2:342 PMID: 20641196 Ref: (111)In-Benzyl-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-ZHER2:342 PMID: 20641264 Ref: BODIPY-FL-neutravidin-biotin-Cetuximab PMID: 20641313 Ref: Epidermal growth factor conjugated to near-infrared fluorescent quantum dots PMID: 20641330 Ref: Trastuzumab-manganese-doped iron oxide nanoparticles PMID: 20641351 Ref: (111)In-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid- Affibody ZHER2:342-pep2 PMID: 20641379 Ref: (99m)Tc- anti-EGFR monoclonal antibody h-R3 PMID: 20641382 Ref: Cy5.5-Trastuzumab PMID: 20641392 Ref: (111)In-Diethylenetriamine pentaacetic acid-pertuzumab PMID: 20641430 Ref: Cetuximab-Oregon Green 488 PMID: 20641450 Ref: (111)In-CHX-A"-diethylenepentaacetic acid-Affibody ZHER2:2395-Cys PMID: 20641462 Ref: (99m)Tc-Hydrazinonicotinamide-epidermal growth factor PMID: 20641466 Ref: Trastuzumab-rhodamine green PMID: 20641468 Ref: (111)In-CHX-A"-Diethylenetriamine pentaacetic acid-(ZEGFR:955)2 PMID: 20641502 Ref: (99m)Tc-Ethylenedicysteine-C225 PMID: 20641507 Ref: (111)In-Benzyl-diethylenetriaminepentaacetic acid-ZHER2:342 PMID: 20641524 Ref: [O-(11)C-methyl]4-N-(3-Bromoanilino)-6,7-dimethoxyquinazoline PMID: 20641571 Ref: (188)Re-Labeled humanized monoclonal anti-epidermal growth factor receptor antibody PMID: 20641577 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-cetuximab PMID: 20641633 Ref: (68)Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-Epidermal growth factor PMID: 20641634 Ref: (111)In-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-AB.Fab4D5 PMID: 20641705 Ref: Quantum dot-trastuzumab PMID: 20641720 Ref: (99m)Tc-Affibody ZHER2:2395-Cys PMID: 20641788 Ref: IRDye 800CW-Epidermal growth factor PMID: 20641801 Ref: (111)In-BZ-Diethylenetriaminepentaacetic acid-ZEGFR:1907 PMID: 20641849 Ref: Cy5.5 conjugated anti-epidermal growth factor receptor monoclonal antibody PMID: 20641853 Ref: (177)Lu-Labeled humanized monoclonal antibody against human epidermal growth factor receptor 2 PMID: 20641866 Ref: Cy5.5-Epidermal growth factor PMID: 20641899 Ref: (111)In-1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide-Affibody ZHER2:2395-Cys PMID: 20641906 Ref: IRDye 700DX-Labeled annexin V PMID: 20641913 Ref: (99m)Tc-Mercaptoacetyl-Ser-Ser-Ser-Affibody ZHER2:342 PMID: 20641924 Ref: (99m)Tc-Mercaptoacetyl-Gly-Gly-Gly-Affibody ZHER2:342 PMID: 20641926 Ref: (99m)Tc-Mercaptoacetyl-Glu-Glu-Glu-Affibody ZHER2:342 PMID: 20641930 Ref: (125)I-Labeled anti-epidermal growth factor receptor human Fab antibody fragment PMID: 20642017 Ref: Alexa Fluor 750-ZHER2:342 Affibody PMID: 20662137 Ref: DY-682-Albumin-binding domain-fused-ZHER2:342 Affibody PMID: 20845546 Ref: IRDye 800-Anti-epidermal growth factor receptor Affibody PMID: 20845547 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-panitumumab PMID: 20945561 Ref: (68)Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-synthetic HER2 specific Affibody ZHER2:342-pep2 PMID: 21086574 Ref: (86)Y-CHX-A''-Diethylenetriamine pentaacetic acid-cetuximab PMID: 21086575 Ref: Alexa Fluor 750-albumin-binding domain-fused-(ZHER2:342)2 Affibody PMID: 21491705 Ref: (124)I-Labeled anti-HER2-specific C6.5 diabody PMID: 21834183 Ref: (86)Y-CHX-A''-diethylenetriamine pentaacetic acid-panitumumab PMID: 22171389 Ref: (18)F-1,4,7-Triazacyclononane-1,4,7-triacetic acid-10-maleimidoethylacetamide-Affibody ZHER2:2395 PMID: 22479718 Ref: (89)Zr-Desferrioxamine p-isothiocyanatobenzyl-anti-EGFR nanobody 7D12 PMID: 22696779 Ref: (68)Ga-Desferrioxamine p-isothiocyanatobenzyl-anti-EGFR nanobody 7D12 PMID: 22696780 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-(Gly-Ser-Gly)-Lys-Cys-Cys-Tyr-Ser-Leu PMID: 22787682 Ref: (64)Cu-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-(Gly-Ser-Gly) -Lys-Cys-Cys-Tyr-Ser-Leu PMID: 22787683 Ref: (64)Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-(Gly-Ser-Gly)-Lys-Cys-Cys-Tyr-Ser-Leu PMID: 22787684 Ref: IRDye 800CW-Anti-epidermal growth factor receptor nanobody 7D12 PMID: 22787693 Ref: (99m)Tc(CO)3-Anti-epidermal growth factor receptor nanobody 8B6 PMID: 22787694 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-epidermal growth factor receptor-binding fibronectin domain E13.4.3' PMID: 22896860 Ref: (111)In/(125)I/(99m)Tc-Labeled N-terminus tri-(histidine-glutamate) (HE)3-tagged and N- or C-terminus hexahistidine (H6)-tagged anti-epidermal growth factor receptor Affibody ZHER2:342-C PMID: 22896861 Ref: Cy5.5-Ac-Cys-ZEGFR:1907 PMID: 22973578 Ref: [(111)In-1,4,7-Triazacyclononane,1-glutaric acid-4,7-acetic acid-10-maleimidoethylacetamide-Cys(61)]-Affibody ZHER2:2395 PMID: 22993871 Ref: (111)In-2-(4,7,10-Tris(carboxymethyl)-1,4,7,10-tetracyclododecan-1-yl)pentanedioi c acid-Trastuzumab PMID: 22993872 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-human serum albumin-Ac-Cys-ZEGFR:1907 PMID: 23035309 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidethylacetamide-Ac-Cys-ZEGFR:1907 PMID: 23035311 Ref: QD800-Polyethylene glycol-Cys-ZHER2:342 Affibody PMID: 23101053 Ref: ZHER2:342 Affibody-polyethylene glycol-superparamagnetic iron oxide nanoparticles PMID: 23101054 Ref: N-[2-(4-[(18)F]Fluorobenzamido)ethyl]maleimide-Cys-ZEGFR:1907 PMID: 23136679 Ref: (177)Lu-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-human serum albumin-Ac-Cys-ZEGFR:1907 PMID: 23166961 Ref: Cy5.5-8-Amino-octanoic acid-Ser-Cys-Pro-Pro-Trp-Gln-Glu-Trp-His-Asn-Phe-Met-Pro-Phe-NH2 PMID: 23166962 Ref: (68)Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-HER2-specific Affibody ZHER2:2891 PMID: 23256220 Ref: N(epsilon)-(3-[(131)I]Iodobenzoyl)-Lys(5)-N(alpha)-maleimido-Gly(1)-GEEEK-anti-HE R2 nanobody 5F7GGC PMID: 23556153 Ref: QD800-Anti-epidermal growth factor receptor monoclonal antibody nanoparticles PMID: 23586108 Ref: IRDye 800-albumin-binding domain-fused-ZHER2:342 Affibody PMID: 23785735 |
Ref: Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers. PMID: 15480783 Ref: Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. PMID: 15486348 Ref: Impact of EGFR expression on colorectal cancer patient prognosis and survival. PMID: 15598946 Ref: New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. PMID: 15655420 Ref: Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. PMID: 15668269 Ref: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. PMID: 15677699 Ref: Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. PMID: 15701846 Ref: H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. PMID: 15713896 Ref: Clinical experience with monoclonal antibodies to epidermal growth factor receptor. PMID: 15717942 Ref: Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies. PMID: 15717992 Ref: Throwing new light on lung cancer pathogenesis: updates on three recent topics. PMID: 15723649 Ref: The epidermal growth factor receptor as a target for colorectal cancer therapy. PMID: 15726506 Ref: Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. PMID: 15743179 Ref: A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. PMID: 15744593 Ref: Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. PMID: 15746034 Ref: Extracellular cysteine/cystine redox regulates the p44/p42 MAPK pathway by metalloproteinase-dependent epidermal growth factor receptor signaling. PMID: 15746213 Ref: IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. PMID: 15749028 Ref: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. PMID: 15753357 Ref: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. PMID: 15753456 Ref: Inhibitors of the epidermal growth factor receptor in apple juice extract. PMID: 15759309 Ref: Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. PMID: 15788691 Ref: (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. PMID: 15814656 Ref: The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. PMID: 15816107 Ref: Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. PMID: 15818163 Ref: Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. PMID: 15821783 Ref: Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients. PMID: 15823708 Ref: EGF receptor inhibition: attacks on multiple fronts. PMID: 15837615 Ref: First-line therapy for advanced colorectal cancer. PMID: 15847706 Ref: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. PMID: 15863375 Ref: Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. PMID: 15867367 Ref: Relevance of EGFR expression in colorectal cancer. PMID: 15870082 Ref: A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. PMID: 15870719 Ref: Epidermal growth factor receptor as a target for chemotherapy. PMID: 15871762 Ref: Impact of EGFR expression on colorectal cancer patient prognosis and survival: a response. PMID: 15871994 Ref: Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. PMID: 15880563 Ref: Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells. PMID: 15888451 Ref: Molecularly targeted therapy for gastrointestinal cancer. PMID: 15892618 Ref: HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. PMID: 15899817 Ref: [Activity of the National Oncology R&D Consortium in 2004]. PMID: 15902326 Ref: Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues. PMID: 15908435 Ref: Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. PMID: 15922858 Ref: Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and tumour spreading. PMID: 15923435 Ref: Molecular markers that predict response to colon cancer therapy. PMID: 15934813 Ref: Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. PMID: 15947929 Ref: Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. PMID: 15967033 Ref: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. PMID: 15980160 Ref: Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. PMID: 15994962 Ref: Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. PMID: 16010411 Ref: Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. PMID: 16012179 Ref: Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. PMID: 16024629 Ref: Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. PMID: 16041691 Ref: EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. PMID: 16053920 Ref: Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. PMID: 16059652 Ref: Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model. PMID: 16061873 Ref: Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. PMID: 16076691 Ref: Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. PMID: 16098254 Ref: Cetuximab therapy and symptomatic hypomagnesemia. PMID: 16106027 Ref: Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. PMID: 16113092 Ref: Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. PMID: 16115757 Ref: Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. PMID: 16117976 Ref: Trans-10,cis-12, not cis-9,trans-11, conjugated linoleic acid decreases ErbB3 expression in HT-29 human colon cancer cells. PMID: 16127743 Ref: Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines. PMID: 16138001 Ref: Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. PMID: 16138927 Ref: Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. PMID: 16139803 Ref: Unusually large colon cancer cutaneous and subcutaneous metastases occurring in resection scars. PMID: 16150230 Ref: Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line. PMID: 16151650 Ref: Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. PMID: 16166444 Ref: Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. PMID: 16199108 Ref: Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer. PMID: 16211285 Ref: Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. PMID: 16213893 Ref: The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. PMID: 16222152 Ref: Lysophosphatidic acid transactivates both c-Met and epidermal growth factor receptor, and induces cyclooxygenase-2 expression in human colon cancer LoVo cells. PMID: 16237757 Ref: Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. PMID: 16243822 Ref: Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients? PMID: 16264980 Ref: [Biotherapy in colorectal cancer]. PMID: 16292207 Ref: Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. PMID: 16317264 Ref: Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. PMID: 16319527 Ref: Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. PMID: 16330971 Ref: Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer. PMID: 16336750 Ref: Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. PMID: 16336751 Ref: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. PMID: 16336752 Ref: Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer. PMID: 16336753 Ref: Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? PMID: 16336755 Ref: Molecular mechanisms and targeting of colorectal cancer. PMID: 16360005 Ref: Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. PMID: 16361624 Ref: EGFR/VEGF signalling pathway in colorectal cancer: the way we are! PMID: 16387661 Ref: [EGFR expression in colorectal cancer and role in tumorigenesis]. PMID: 16387663 Ref: [Prognostic value of EGFR in colorectal cancer]. PMID: 16387664 Ref: [Pharmacological skills for targeting EGFR and VEGF]. PMID: 16387665 Ref: [Targeting the epidermal growth factor receptor in colorectal cancer: clinical results]. PMID: 16387666 Ref: [Targeted therapies and radiotherapy in colorectal cancer]. PMID: 16387668 Ref: The role of cetuximab in the therapy of previously treated advanced colorectal cancer. PMID: 16399433 Ref: Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. PMID: 16399434 Ref: Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation. PMID: 16400742 Ref: EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. PMID: 16416603 Ref: [Prognostic/predictive role of epidermal growth factor receptor (EGFR) in colorectal carcinoma]. PMID: 16440643 Ref: Cetuximab in the treatment of colorectal cancer. PMID: 16555987 Ref: Epidermal growth factor receptor inhibitors in cancer treatment. PMID: 16555994 |
Ref: [Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma]. PMID: 15991047 Ref: Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. PMID: 16082388 Ref: Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. PMID: 16170359 Ref: Somatic mutations of the ERBB4 kinase domain in human cancers. PMID: 16187281 Ref: Expression of caveolin-1 is correlated with Akt-1 in colorectal cancer tissues. PMID: 16202996 Ref: Hypoxia induces epithelial amphiregulin gene expression in a CREB-dependent manner. PMID: 16207795 Ref: Lysophosphatidic acid-induced effects in human colon carcinoma DLD1 cells are partially dependent on transactivation of epidermal growth factor receptor. PMID: 16289596 Ref: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. PMID: 16303861 Ref: In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. PMID: 16320055 Ref: The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. PMID: 16353180 Ref: Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. PMID: 16368433 Ref: Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. PMID: 16391786 Ref: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. PMID: 16397024 Ref: Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. PMID: 16397041 Ref: Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. PMID: 16397255 Ref: Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. PMID: 16432186 Ref: Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. PMID: 16446337 Ref: Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer. PMID: 16466998 Ref: [Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer]. PMID: 16483941 Ref: 9-Hydroxystearic acid interferes with EGF signalling in a human colon adenocarcinoma. PMID: 16487928 Ref: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. PMID: 16508634 Ref: FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression. PMID: 16510588 Ref: EGFR in colorectal cancer: more than a simple receptor. PMID: 16524971 Ref: Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. PMID: 16532444 Ref: Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. PMID: 16548776 Ref: Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. PMID: 16562649 Ref: Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation. PMID: 16574647 Ref: Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. PMID: 16596188 Ref: Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. PMID: 16614884 Ref: Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. PMID: 16618579 Ref: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. PMID: 16618717 Ref: EGF receptor-related protein (ERRP) inhibits invasion of colon cancer cells and tubule formation by endothelial cells in vitro. PMID: 16619503 Ref: New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor. PMID: 16622275 Ref: Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer. PMID: 16637508 Ref: Individualizing chemotherapeutic treatment of colorectal cancer. PMID: 16641252 Ref: Pharmacogenomics: from bedside to clinical practice. PMID: 16651374 Ref: Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption. PMID: 16673807 Ref: Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies. PMID: 16675911 Ref: Tissue microarray analysis of EGFR gene amplification and gain in Bulgarian patients with colorectal cancer. PMID: 16679780 Ref: Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. PMID: 16688779 Ref: Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. PMID: 16690221 Ref: Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. PMID: 16736979 Ref: Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. PMID: 16737669 Ref: Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. PMID: 16740703 Ref: Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. PMID: 16757132 Ref: EGFR expression in colon cancer: a break in the clouds. PMID: 16766589 Ref: Incidence and management of bevacizumab-related toxicities in colorectal cancer. PMID: 16774493 Ref: EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. PMID: 16777680 Ref: Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. PMID: 16788380 Ref: Panitumumab: a new anti-EGFR antibody for the treatment of advanced colorectal cancer. PMID: 16796785 Ref: Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. PMID: 16803682 Ref: Stress-induced phosphorylation of caveolin-1 and p38, and down-regulation of EGFr and ERK by the dietary lectin jacalin in two human carcinoma cell lines. PMID: 16817319 Ref: Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. PMID: 16818638 Ref: Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. PMID: 16818703 Ref: Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. PMID: 16819546 Ref: [Double sites short hairpin RNAs targeting epidermal growth factor receptor to promote colon cancer cells apoptosis and enhance 5-fluorouracil chemotherapy effect]. PMID: 16836928 Ref: Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. PMID: 16839708 Ref: Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. PMID: 16847424 Ref: Protein kinase C alpha but not PKCzeta suppresses intestinal tumor formation in ApcMin/+ mice. PMID: 16849539 Ref: Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. PMID: 16857822 Ref: Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. PMID: 16885373 Ref: Epidermal growth factor receptor targeting in cancer. PMID: 16890793 Ref: Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. PMID: 16891475 Ref: Molecular determinants of irinotecan efficacy. PMID: 16894565 Ref: Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. PMID: 16906777 Ref: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. PMID: 16909423 Ref: Cetuximab in squamous cell carcinoma of the head and neck. PMID: 16922611 Ref: Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. PMID: 16926635 Ref: Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. PMID: 16928826 Ref: Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. PMID: 16937523 Ref: Role of panitumumab in the management of metastatic colorectal cancer. PMID: 16945167 Ref: Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease. PMID: 16952747 Ref: [Epidermal growth factor receptor inhibitors side effects]. PMID: 16956561 Ref: Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. PMID: 17007015 Ref: Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods. PMID: 17016647 Ref: Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. PMID: 17026790 Ref: Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. PMID: 17026791 Ref: Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. PMID: 17030643 Ref: Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. PMID: 17030644 Ref: Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. PMID: 17044774 Ref: Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. PMID: 17045403 Ref: Recent developments in colorectal cancer treatment by monoclonal antibodies. PMID: 17049015 Ref: Panitumumab in colon cancer: a review and summary of ongoing trials. PMID: 17049019 Ref: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. PMID: 17050875 Ref: Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines. PMID: 17059835 Ref: Does the EGFR and VEGF expression predict the prognosis in colon cancer? PMID: 17085940 Ref: Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa. PMID: 17088913 Ref: Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? PMID: 17089034 Ref: Panitumumab: in the treatment of metastatic colorectal cancer. PMID: 17100412 Ref: [Long-term beneficial effects of cetuximab in a woman with metastasised rectal carcinoma without expression of the epidermal growth factor receptor]. PMID: 17152334 Ref: Panitumumab. PMID: 17171190 Ref: Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. PMID: 17189393 Ref: Lack of the type III epidermal growth factor receptor mutation in colorectal cancer. PMID: 17214357 Ref: [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan]. PMID: 17236550 Ref: Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. PMID: 17241515 Ref: Higher expression of epidermal growth factor receptor is associated with extracellular matrix metalloprotease inducer in colorectal adenocarcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. PMID: 17264401 Ref: Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. PMID: 17354514 Ref: Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. PMID: 17438669 Ref: Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity. PMID: 18473962 Ref: New insights into the molecular pathogenesis of colorectal cancer. PMID: 20151020 |
Ref: HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. PMID: 16882699 Ref: Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. PMID: 16937104 Ref: Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. PMID: 17001310 Ref: Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. PMID: 17060407 Ref: [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid]. PMID: 17146641 Ref: Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. PMID: 17149612 Ref: Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. PMID: 17169374 Ref: Epidermal growth factor receptor and rectal cancer: in regard to Kim et al. (Int J Radiat Oncol Biol Phys 2006;66:195-200). PMID: 17189081 Ref: Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. PMID: 17189670 Ref: Regulation of oxidant-induced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling. PMID: 17220428 Ref: Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas. PMID: 17222249 Ref: Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. PMID: 17222808 Ref: A new EGFR inhibitor induces apoptosis in colon cancer cells. PMID: 17227671 Ref: Neurotensin stimulates expression of early growth response gene-1 and EGF receptor through MAP kinase activation in human colonic epithelial cells. PMID: 17230532 Ref: The epidermal growth factor receptor and human topoisomerases represent potential cellular targets of oligomeric procyanidins. PMID: 17230588 Ref: A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. PMID: 17234777 Ref: Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. PMID: 17234795 Ref: Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. PMID: 17250463 Ref: Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. PMID: 17255274 Ref: A simple method for the routine detection of somatic quantitative genetic alterations in colorectal cancer. PMID: 17258723 Ref: Co-expression of EGF receptor, TGFalpha and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis. PMID: 17265080 Ref: A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. PMID: 17289894 Ref: Cimetidine inhibits epidermal growth factor-induced cell signaling. PMID: 17295779 Ref: Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. PMID: 17308052 Ref: A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. PMID: 17311026 Ref: Targeted therapy in colorectal cancer. PMID: 17311700 Ref: Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. PMID: 17346275 Ref: Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. PMID: 17355997 Ref: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. PMID: 17363584 Ref: Epidermal growth factor receptor and prognosis in colon cancer: a crack in the wall? PMID: 17375355 Ref: Apple polyphenols diminish the phosphorylation of the epidermal growth factor receptor in HT29 colon carcinoma cells. PMID: 17427262 Ref: Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. PMID: 17445998 Ref: PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment? PMID: 17447062 Ref: Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. PMID: 17460778 Ref: Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. PMID: 17466895 Ref: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. PMID: 17470858 Ref: Quantitative imaging of apoptosis commitment in colorectal tumor cells. PMID: 17511782 Ref: Clinical management of cutaneous toxicity of anti-EGFR agents. PMID: 17520582 Ref: Cetuximab in colon cancer. PMID: 17520583 Ref: The future of anti-EGFR therapy. PMID: 17520586 Ref: FDA drug approval summary: panitumumab (Vectibix). PMID: 17522246 Ref: Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. PMID: 17530019 Ref: Regression of early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related protein. PMID: 17545620 Ref: [Correlations of c-erb-B2, EGFR, and TGF-alpha expression to recurrence of Dukes'A and B colorectal carcinoma]. PMID: 17562274 Ref: EGFR-targeted therapies in colorectal cancer. PMID: 17566832 Ref: Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. PMID: 17575224 Ref: Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. PMID: 17578896 Ref: Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. PMID: 17579627 Ref: Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? PMID: 17588349 Ref: Panitumumab a novel drug in cancer treatment. PMID: 17591813 Ref: The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. PMID: 17593628 Ref: First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. PMID: 17594712 Ref: Expression of epidermal growth factor receptor as a predictive factor for rectal cancer. PMID: 17604465 Ref: Cetuximab: appraisal of a novel drug against colorectal cancer. PMID: 17607921 Ref: Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. PMID: 17608727 Ref: The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. PMID: 17616711 Ref: Panitumumab in colorectal cancer. PMID: 17627455 Ref: TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. PMID: 17636117 Ref: Identification and characterization of ErbB-3-binding protein-1 as a target for immunotherapy. PMID: 17641068 Ref: Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer. PMID: 17649779 Ref: Targeting the epidermal growth factor receptor in colorectal carcinoma. PMID: 17666985 Ref: Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. PMID: 17666987 Ref: Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. PMID: 17671148 Ref: Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. PMID: 17671655 Ref: Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. PMID: 17671985 Ref: Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. PMID: 17674041 Ref: [Cetuximab]. PMID: 17687200 Ref: Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer. PMID: 17715697 Ref: Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. PMID: 17721276 Ref: Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. PMID: 17762902 Ref: Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. PMID: 17804738 Ref: Targeted therapies in colorectal carcinoma: addressing toxicities associated with EGFR inhibitors. PMID: 17824555 Ref: [Protein overexpression and gene copy number of EGFR and HER2 in colorectal carcinoma]. PMID: 17845756 Ref: Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. PMID: 17851837 Ref: LRIG1 expression in colorectal cancer. PMID: 17851870 Ref: Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. PMID: 17877615 Ref: Oncologists' current opinion on the treatment of colon carcinoma. PMID: 17896910 Ref: Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. PMID: 17909047 Ref: Targeted therapy in rectal cancer. PMID: 17910311 Ref: Molecular markers in colorectal cancer: genetic bases for a customised treatment. PMID: 17921101 Ref: From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. PMID: 17921999 Ref: Molecular targets in squamous cell carcinoma of the head and neck. PMID: 17962911 Ref: [Predictive factors of response to targeted therapies: the example of colorectal cancer]. PMID: 17965001 Ref: Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. PMID: 17975157 Ref: Exploiting novel molecular targets in gastrointestinal cancers. PMID: 17990350 Ref: Cetuximab for the treatment of colorectal cancer. PMID: 18003960 Ref: Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. PMID: 18006816 Ref: First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. PMID: 18021486 Ref: The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer. PMID: 18021487 Ref: Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer. PMID: 18021489 Ref: Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. PMID: 18039422 Ref: [Treatment with cetuximab in metastatic colorectal cancer patients who do not express the epidermal growth factor receptor]. PMID: 18052628 Ref: Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. PMID: 18054559 Ref: Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. PMID: 18084614 Ref: [EGFR and colorectal cancer: what's new?]. PMID: 18185468 Ref: A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients. PMID: 18361806 Ref: Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. PMID: 19360146 Ref: Update on targeted agents for adjuvant treatment of colon cancer in 2006. PMID: 19360148 Ref: Cetuximab in the management of colorectal cancer. PMID: 19707318 Ref: Clinical management of cutaneous toxicity of anti-EGFR agents. PMID: 28207115 Ref: Cetuximab in colon cancer. PMID: 28207116 Ref: The future of anti-EGFR therapy. PMID: 28207119 |
Ref: Epidermal growth factor receptor in colorectal carcinoma: correlation with clinico-pathological prognostic factors. PMID: 17711501 Ref: Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. PMID: 17918158 Ref: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. PMID: 17974556 Ref: A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. PMID: 17986625 Ref: Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. PMID: 17987340 Ref: Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. PMID: 17996386 Ref: Targeting the epidermal growth factor receptor in metastatic colorectal cancer. PMID: 18006328 Ref: A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. PMID: 18059397 Ref: Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. PMID: 18064605 Ref: First-line single-agent cetuximab in patients with advanced colorectal cancer. PMID: 18073221 Ref: Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. PMID: 18097777 Ref: EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. PMID: 18154448 Ref: Cetuximab, its clinical use and future perspectives. PMID: 18176106 Ref: Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. PMID: 18182986 Ref: Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. PMID: 18206383 Ref: EGFR and colon cancer: a clinical view. PMID: 18208787 Ref: [Potential combination of target therapy and radiation therapy in GI tract cancers]. PMID: 18226575 Ref: [Predictive factors of response to anti-EGFR treatments in colorectal cancer]. PMID: 18230579 Ref: The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. PMID: 18245483 Ref: A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. PMID: 18272912 Ref: TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. PMID: 18281553 Ref: Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers. PMID: 18286687 Ref: Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. PMID: 18313913 Ref: The AP-2alpha transcription factor is required for the ganglioside GM3-stimulated transcriptional regulation of a PTEN gene. PMID: 18316341 Ref: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. PMID: 18316791 Ref: Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. PMID: 18319715 Ref: Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. PMID: 18324358 Ref: Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib? PMID: 18327586 Ref: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. PMID: 18339877 Ref: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. PMID: 18343240 Ref: Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. PMID: 18347145 Ref: Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. PMID: 18349392 Ref: [Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment]. PMID: 18350301 Ref: Implications of EGFR PharmDx kit for cetuximab eligibility. PMID: 18366301 Ref: Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. PMID: 18381602 Ref: DxS Ltd. PMID: 18384259 Ref: EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? PMID: 18386224 Ref: Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. PMID: 18413774 Ref: Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. PMID: 18413814 Ref: Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. PMID: 18413824 Ref: [Antibody treatment in colorectal cancer--what the surgeon needs to know]. PMID: 18415895 Ref: Oak ellagitannins suppress the phosphorylation of the epidermal growth factor receptor in human colon carcinoma cells. PMID: 18419129 Ref: Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. PMID: 18422755 Ref: Targeted therapy of cancer: new roles for pathologists in colorectal cancer. PMID: 18437170 Ref: EGFR FISH in colorectal cancer: what is the current reality? PMID: 18452847 Ref: Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. PMID: 18454685 Ref: Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. PMID: 18472966 Ref: [Molecular target therapy and chemotherapy for advanced colorectal cancer]. PMID: 18487907 Ref: Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib. PMID: 18497962 Ref: Mechanism of resistance to chemoradiation in p53 mutant human colon cancer. PMID: 18497992 Ref: Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice. PMID: 18499885 Ref: Development of monoclonal antibodies for the treatment of colorectal cancer. PMID: 18499888 Ref: Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group. PMID: 18501069 Ref: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. PMID: 18503402 Ref: Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. PMID: 18506165 Ref: Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance. PMID: 18507034 Ref: A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. PMID: 18544172 Ref: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. PMID: 18577988 Ref: Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. PMID: 18583324 Ref: (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. PMID: 18586691 Ref: Comparison of delphinidin, quercetin and (-)-epigallocatechin-3-gallate as inhibitors of the EGFR and the ErbB2 receptor phosphorylation. PMID: 18618485 Ref: Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. PMID: 18619649 Ref: Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. PMID: 18632722 Ref: VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. PMID: 18636661 Ref: Does hyaluronic acid stimulate tumor growth after endoscopic mucosal resection? PMID: 18637056 Ref: [The RAS paradox of the EGFR-targeted therapy in colorectal cancer]. PMID: 18640895 Ref: KRAS mutation profile in colorectal carcinoma and novel mutation--internal tandem duplication in KRAS. PMID: 18669174 Ref: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. PMID: 18676755 Ref: Pharmacogenetics in colorectal cancer: a systematic review. PMID: 18681783 Ref: Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. PMID: 18691415 Ref: Parallel synthesis and cytotoxicity evaluation of a polyamine-quinone conjugates library. PMID: 18698755 Ref: Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. PMID: 18700047 Ref: Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. PMID: 18701480 Ref: EGFR-immunohistochemistry in colorectal cancer and non-small cell lung cancer: comparison of 3 commercially available EGFR-antibodies. PMID: 18720932 Ref: Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis. PMID: 18769609 Ref: Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment. PMID: 18787354 Ref: Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail. PMID: 18790788 Ref: Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. PMID: 18794099 Ref: Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. PMID: 18794809 Ref: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. PMID: 18802721 Ref: [Molecular targets for colon cancer. VEGF, EGFR - and what else?]. PMID: 18810446 Ref: Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. PMID: 18829558 Ref: Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. PMID: 18922903 Ref: Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. PMID: 18936523 Ref: Targeting EGFR in colorectal cancer. PMID: 18946069 Ref: Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. PMID: 18949375 Ref: Severe acneiform eruption induced by cetuximab (Erbitux). PMID: 18972607 Ref: Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. PMID: 18980548 Ref: Enhanced antitumor activities of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives in vitro and in vivo. PMID: 18983978 Ref: CT staging of colon cancer. PMID: 18996269 Ref: Panitumumab: in metastatic colorectal cancer with wild-type KRAS. PMID: 18998757 Ref: Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. PMID: 19001346 Ref: [Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view]. PMID: 19004722 Ref: [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer]. PMID: 19004723 Ref: [Design of new protocols. Role of molecular biology units?]. PMID: 19004733 Ref: Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. PMID: 19010858 Ref: Id-1: regulator of EGFR and VEGF and potential target for colorectal cancer therapy. PMID: 19014499 Ref: Tanshinone IIA down-regulates the protein expression of ErbB-2 and up-regulates TNF-alpha in colon cancer cells in vitro and in vivo. PMID: 19020785 Ref: [Colorectal carcinoma--molecular markers in clinical routine]. PMID: 19033696 Ref: Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. PMID: 19047118 Ref: Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer. PMID: 19064407 Ref: ErbB antagonists patenting: "playing chess with cancer". PMID: 19075865 Ref: KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition. PMID: 19078954 Ref: EGFR, HER-2 and COX-2 levels in colorectal cancer. PMID: 19102009 Ref: The role of targeted therapy in the treatment of advanced colorectal cancer. PMID: 19238551 Ref: Rationale for combining biotherapy in the treatment of advanced colon cancer. PMID: 19259292 Ref: Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?). PMID: 19343143 Ref: KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors. PMID: 19378369 Ref: Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. PMID: 19707356 Ref: Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems Biology of Tumor Cell-Signaling. PMID: 19763245 Ref: Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor. PMID: 21136888 |
Ref: Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor. PMID: 16632243 Ref: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. PMID: 18669866 Ref: Dual targeting of EGFR and HER-2 in colon cancer cell lines. PMID: 18751705 Ref: Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. PMID: 18790560 Ref: Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with adenomas: a risk factor for colon cancer. PMID: 19010307 Ref: Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. PMID: 19033715 Ref: A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. PMID: 19037088 Ref: Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. PMID: 19047896 Ref: Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study. PMID: 19050903 Ref: Akt-dependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. PMID: 19056378 Ref: Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. PMID: 19058300 Ref: Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. PMID: 19117687 Ref: Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. PMID: 19124237 Ref: p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047. PMID: 19138820 Ref: Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? PMID: 19144681 Ref: [Biomarker for chemotherapy in patients with colorectal cancer]. PMID: 19151559 Ref: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. PMID: 19188670 Ref: Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. PMID: 19221016 Ref: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. PMID: 19223544 Ref: Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade. PMID: 19224142 Ref: Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. PMID: 19229368 Ref: Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. PMID: 19229860 Ref: Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. PMID: 19229991 Ref: [What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?]. PMID: 19231039 Ref: Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR. PMID: 19233916 Ref: Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. PMID: 19236713 Ref: Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. PMID: 19273701 Ref: K-ras mutations in colorectal cancer: a practice changing discovery. PMID: 19274041 Ref: Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. PMID: 19276250 Ref: Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. PMID: 19277036 Ref: Targeting apoptosis as an approach for gastrointestinal cancer therapy. PMID: 19278896 Ref: Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings. PMID: 19279475 Ref: Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. PMID: 19293803 Ref: Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients. PMID: 19309232 Ref: [Neoadjuvant approach for non-metastatic rectal cancer combining radiotherapy and chemotherapy. Biotargeted drugs]. PMID: 19318310 Ref: Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. PMID: 19331154 Ref: P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. PMID: 19331236 Ref: Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. PMID: 19333227 Ref: Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. PMID: 19340455 Ref: KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. PMID: 19352138 Ref: KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. PMID: 19358724 Ref: No functional and transductional significance of specific neuropilin 1 siRNA inhibition in colon carcinoma cell lines lacking VEGF receptor 2. PMID: 19360289 Ref: [Towards an individualized treatment of the colorectal cancer: a new therapy against EGFR opens the way]. PMID: 19361403 Ref: [Metastatic colorectal cancers and targeted therapy against EGFR]. PMID: 19361405 Ref: KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. PMID: 19368524 Ref: Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization. PMID: 19368728 Ref: Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. PMID: 19372555 Ref: Mechanisms of resistance to EGFR inhibitors in head and neck cancer. PMID: 19378324 Ref: Current situation of zalutumumab. PMID: 19379120 Ref: Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. PMID: 19386128 Ref: ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. PMID: 19390858 Ref: Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH. PMID: 19404848 Ref: Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. PMID: 19423505 Ref: Treatment in advanced colorectal cancer: what, when and how? PMID: 19436303 Ref: Gene expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to ellagic acid and its metabolites, urolithins. PMID: 19437480 Ref: A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. PMID: 19439077 Ref: ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases. PMID: 19443355 Ref: Genotyping of K-ras codons 12 and 13 mutations in colorectal cancer by capillary electrophoresis. PMID: 19450806 Ref: High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor. PMID: 19451802 Ref: Skin toxicities associated with epidermal growth factor receptor inhibitors. PMID: 19452131 Ref: Combination of aging and dimethylhydrazine treatment causes an increase in cancer-stem cell population of rat colonic crypts. PMID: 19465005 Ref: The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. PMID: 19471640 Ref: A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. PMID: 19478384 Ref: Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. PMID: 19479664 Ref: Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. PMID: 19480968 Ref: Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. PMID: 19482027 Ref: Genetics: Predictive value of KRAS mutations in chemoresistant CRC. PMID: 19483733 Ref: Molecular targeted treatment and radiation therapy for rectal cancer. PMID: 19506820 Ref: A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. PMID: 19519875 Ref: The effects of epidermal growth factor receptor activation and attenuation of the TGFbeta pathway in an orthotopic model of colon cancer. PMID: 19524264 Ref: Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. PMID: 19526592 Ref: Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models. PMID: 19528458 Ref: Old disease, new targets--part-I, solid malignancies. PMID: 19534378 Ref: Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. PMID: 19534585 Ref: Genetic prognostic and predictive markers in colorectal cancer. PMID: 19536109 Ref: The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. PMID: 19536776 Ref: Clinical biomarkers in oncology: focus on colorectal cancer. PMID: 19537845 Ref: [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy]. PMID: 19542725 Ref: KRAS mutation testing in colorectal cancer. PMID: 19546608 Ref: Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. PMID: 19558693 Ref: (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells. PMID: 19578043 Ref: [Panitumumab-treatment of metastatic colorectal cancer]. PMID: 19581179 Ref: Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. PMID: 19581734 Ref: Down-regulation of epidermal growth factor receptor by selective expansion of a 5'-end regulatory dinucleotide repeat in colon cancer with microsatellite instability. PMID: 19584170 Ref: Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. PMID: 19584908 Ref: Are RAS mutations predictive markers of resistance to standard chemotherapy? PMID: 19597509 Ref: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. PMID: 19603018 Ref: Carbachol induces p70S6K1 activation through an ERK-dependent but Akt-independent pathway in human colonic epithelial cells. PMID: 19615971 Ref: [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment]. PMID: 19620792 Ref: [Cetuximab (Erbitux)]. PMID: 19620819 Ref: KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. PMID: 19632927 Ref: Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. PMID: 19636327 Ref: Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. PMID: 19636422 Ref: Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. PMID: 19636423 Ref: [Chemotherapy and biological treatment in the complex management of large intestinal and rectal carcinomas. When, why, how?]. PMID: 19642320 Ref: [Monoclonal antibodies therapies for colorectal cancer: cetuximab, panitumumab and bevacizumab]. PMID: 19642458 Ref: Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology. PMID: 19644023 Ref: [Tissue microarray (TMA) validated progression markers in colorectal cancer using antibody microarrays]. PMID: 19648079 Ref: A novel K-ras mutation in colorectal cancer. A case report and literature review. PMID: 19661358 Ref: Anti-EGFR therapy in colorectal cancer: how to choose the right patient. PMID: 19663767 Ref: [Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation]. PMID: 19671328 Ref: Oncogenic activating mutations are associated with local copy gain. PMID: 19671679 Ref: Receptor tyrosine phosphatases control tracheal tube geometries through negative regulation of Egfr signaling. PMID: 19675131 Ref: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. PMID: 19679400 Ref: Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. PMID: 19690388 Ref: [Pathology: on the way to molecular analysis]. PMID: 19692190 Ref: [Predictive biomarkers in colorectal cancer]. PMID: 19694362 Ref: [Targeted biotherapy: a revolution in the management of patients with colorectal cancer?]. PMID: 19717258 Ref: Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. PMID: 19723673 Ref: Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. PMID: 19724847 Ref: [Expression and clinical significance of metastasis-related tumor markers in colorectal cancer]. PMID: 19728913 Ref: Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. PMID: 19732064 Ref: Ursolic acid inhibits proliferation and induces apoptosis of HT-29 colon cancer cells by inhibiting the EGFR/MAPK pathway. PMID: 19735099 Ref: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. PMID: 19738126 Ref: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. PMID: 19738166 Ref: Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. PMID: 19739273 Ref: Cetuximab-associated pulmonary toxicity. PMID: 19739274 Ref: [Construction and identification of CerbB-2 siRNA expression plasmid and its transfer into human colon cancer cell lines HT-29]. PMID: 19778814 Ref: An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. PMID: 19789347 Ref: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PMID: 19806185 Ref: Antisense phosphorothioate oligodeoxynucleic acid for CD10 suppresses liver metastasis of colorectal cancer. PMID: 19816087 Ref: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. PMID: 19826350 Ref: Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer. PMID: 19829092 Ref: Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. PMID: 19832985 Ref: Extracellular ATP activates MAP kinase cascades through a P2Y purinergic receptor in the human intestinal Caco-2 cell line. PMID: 19836435 Ref: Curcumin synergizes with resveratrol to inhibit colon cancer. PMID: 19838927 Ref: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. PMID: 19884549 Ref: Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2. PMID: 19903783 Ref: Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. PMID: 19917537 Ref: Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. PMID: 19923311 Ref: KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. PMID: 19934290 Ref: DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. PMID: 19946413 Ref: Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. PMID: 19956394 Ref: Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. PMID: 20008849 Ref: The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP. PMID: 20009541 Ref: Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism? PMID: 20016807 Ref: KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PMID: 20020061 Ref: [Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view]. PMID: 20034866 Ref: [Prognostic role of KRAS mutation in colorectal cancer]. PMID: 20034867 Ref: [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients]. PMID: 20034868 Ref: [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis]. PMID: 20034869 Ref: [Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view]. PMID: 20034870 Ref: Autophagy: novel action of panitumumab in colon cancer. PMID: 20044619 Ref: [Validation study of KRAS mutation in colorectal cancer]. PMID: 20071308 Ref: Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. PMID: 20072938 Ref: EGFR signaling and drug discovery. PMID: 20130423 Ref: The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. PMID: 20130433 Ref: The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma. PMID: 20130434 Ref: DNA/RNA markers for colorectal cancer risk in preserved stool specimens: a pilot study. PMID: 20210241 Ref: Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy. PMID: 20300583 Ref: [Biomarkers and anti-EGFR therapies for KRAS wild-type tumors in metastatic colorectal cancer patients]. PMID: 20432670 Ref: Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. PMID: 20616891 Ref: First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. PMID: 20616896 Ref: Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. PMID: 20616903 Ref: Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target. PMID: 20698358 Ref: Evolving role of cetuximab in the treatment of colorectal cancer. PMID: 21188126 Ref: Effect of butyrate on the heregulin/ErbB-mediated proliferation of human colorectal cancer cells. PMID: 21475856 Ref: Medical treatment of advanced colorectal cancer in 2009. PMID: 21789113 Ref: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. PMID: 21789120 Ref: Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies. PMID: 29788610 |
Ref: Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial. PMID: 19396400 Ref: Integration of panitumumab into the treatment of colorectal cancer. PMID: 19616446 Ref: Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. PMID: 19700342 Ref: Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases. PMID: 19701635 Ref: Translational up-regulation of Aurora-A in EGFR-overexpressed cancer. PMID: 19799648 Ref: In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. PMID: 19852961 Ref: MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. PMID: 19862647 Ref: The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. PMID: 19876926 Ref: The EGFR pathway as an example for genotype: phenotype correlation in tumor genes. PMID: 19882270 Ref: Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. PMID: 19886911 Ref: Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. PMID: 19903175 Ref: Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. PMID: 19935791 Ref: KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. PMID: 19936839 Ref: Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. PMID: 19937133 Ref: KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. PMID: 19952717 Ref: Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer. PMID: 19954416 Ref: [Pathological diagnosis for individualized therapy of colorectal cancer]. PMID: 19957085 Ref: Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. PMID: 19997103 Ref: Palliative treatment of unresectable metastatic colorectal cancer. PMID: 20001430 Ref: Current progress in targeted therapy for colorectal cancer. PMID: 20010514 Ref: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. PMID: 20022809 Ref: KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. PMID: 20049644 Ref: Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. PMID: 20049837 Ref: Cetuximab in the treatment of rheumatoid arthritis. PMID: 20051754 Ref: Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells. PMID: 20056314 Ref: Mechanisms of resistance to HER family targeting antibodies. PMID: 20064507 Ref: The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. PMID: 20067946 Ref: [Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]. PMID: 20080456 Ref: Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab. PMID: 20085858 Ref: Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. PMID: 20086114 Ref: Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. PMID: 20088793 Ref: Colorectal cancer in review: the role of the EGFR pathway. PMID: 20095919 Ref: Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. PMID: 20099280 Ref: Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. PMID: 20100958 Ref: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. PMID: 20100961 Ref: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. PMID: 20103678 Ref: Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg PMID: 20117921 Ref: Incorporating new data on colorectal cancer into nursing practice. PMID: 20118032 Ref: Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. PMID: 20133499 Ref: Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. PMID: 20147967 Ref: The molecular therapy of colorectal cancer. PMID: 20171980 Ref: Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? PMID: 20180626 Ref: REG IV overexpression in an early stage of colorectal carcinogenesis: an immunohistochemical study. PMID: 20183800 Ref: Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer. PMID: 20184776 Ref: Bile acid regulates MUC2 transcription in colon cancer cells via positive EGFR/PKC/Ras/ERK/CREB, PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative JNK/c-Jun/AP-1 pathway. PMID: 20198339 Ref: Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. PMID: 20222160 Ref: [Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests]. PMID: 20229816 Ref: Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. PMID: 20234366 Ref: Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. PMID: 20332435 Ref: The molecular pathology of cancer. PMID: 20351699 Ref: Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. PMID: 20361188 Ref: Molecular predictive and prognostic markers in colon cancer. PMID: 20363564 Ref: Targeting NF-kappaB for colorectal cancer. PMID: 20367537 Ref: KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. PMID: 20372787 Ref: Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. PMID: 20381235 Ref: Oncogenic mutations as predictive factors in colorectal cancer. PMID: 20383189 Ref: Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. PMID: 20385028 Ref: [Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)]. PMID: 20385517 Ref: Predictive biomarker validation in practice: lessons from real trials. PMID: 20392785 Ref: Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. PMID: 20397915 Ref: Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. PMID: 20398370 Ref: Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). PMID: 20399639 Ref: Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. PMID: 20399983 Ref: Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives. PMID: 20406173 Ref: MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. PMID: 20406885 Ref: Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. PMID: 20413299 Ref: Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. PMID: 20420953 Ref: Current issues in the targeted therapy of advanced colorectal cancer. PMID: 20423677 Ref: KRAS testing and its importance in colorectal cancer. PMID: 20425075 Ref: Recent patents and advances in genomic biomarker discovery for colorectal cancers. PMID: 20426761 Ref: Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation. PMID: 20427690 Ref: p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation. PMID: 20453886 Ref: Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. PMID: 20459770 Ref: Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. PMID: 20472490 Ref: [Anti-epidermal growth factor receptor monoclonal antibodies induced adverse events]. PMID: 20495307 Ref: [The anti EGFR antibody indication between the Japanese and overseas guidelines]. PMID: 20495310 Ref: BRAF mutations in sporadic colorectal carcinoma from polish patients. PMID: 20496269 Ref: Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. PMID: 20504250 Ref: Practical and molecular evaluation of colorectal cancer: new roles for the pathologist in the era of targeted therapy. PMID: 20524863 Ref: Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association. PMID: 20525880 Ref: Integrating molecular diagnostics into anticancer drug discovery. PMID: 20531274 Ref: Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PMID: 20532039 Ref: [Antibody therapy in cancer]. PMID: 20535960 Ref: [Transition of chemotherapy for metastatic colorectal cancer and recent advances]. PMID: 20535969 Ref: Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. PMID: 20550212 Ref: Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? PMID: 20550522 Ref: Targeted treatments in colorectal cancer: state of the art and future perspectives. PMID: 20551469 Ref: Understanding resistance to EGFR inhibitors-impact on future treatment strategies. PMID: 20551942 Ref: New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. PMID: 20554751 Ref: Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. PMID: 20563247 Ref: The role of targeted agents in preoperative chemoradiation for rectal cancer. PMID: 20564106 Ref: An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models. PMID: 20569491 Ref: Genomic and biological characterization of exon 4 KRAS mutations in human cancer. PMID: 20570890 Ref: [Current medicinal treatment of metastasized colorectal carcinoma]. PMID: 20574792 Ref: A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. PMID: 20584808 Ref: Intranuclear translocation signaling of HB-EGF carboxy-terminal fragment and mucosal defense through cell proliferation and migration in digestive tracts. PMID: 20588025 Ref: Therapeutic modulation of k-ras signaling in colorectal cancer. PMID: 20594936 Ref: EGFR expression variance in paired colorectal cancer primary and metastatic tumors. PMID: 20595818 Ref: Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells. PMID: 20596675 Ref: Ursodeoxycholic acid and chemoprevention of colorectal cancer. PMID: 20609543 Ref: T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. PMID: 20616015 Ref: Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. PMID: 20624167 Ref: Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer. PMID: 20630850 Ref: [Recent developments of pharmacogenomics in the treatment of colorectal cancers]. PMID: 20637356 Ref: Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. PMID: 20652941 Ref: Multimodality therapy for adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. PMID: 20676879 Ref: Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. PMID: 20680104 Ref: KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. PMID: 20680106 Ref: Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. PMID: 20713879 Ref: Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. PMID: 20716165 Ref: Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. PMID: 20718704 Ref: KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence. PMID: 20718705 Ref: Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies. PMID: 20718710 Ref: UVRAG mutations associated with microsatellite unstable colon cancer do not affect autophagy. PMID: 20724836 Ref: Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. PMID: 20726007 Ref: High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles. PMID: 20732413 Ref: BRAF testing in advanced colorectal cancer: is it ready for prime time? PMID: 20733556 Ref: Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. PMID: 20798559 Ref: Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. PMID: 20810384 Ref: [Effect of anti-EGFR monoclonal antibody on chemosensitivity of human colon cancer cells and the mechanism]. PMID: 20813673 Ref: [mRNA quantification. The next challenge in routine diagnostics]. PMID: 20824431 Ref: Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. PMID: 20826046 Ref: Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. PMID: 20842128 Ref: [Current options and principles of pathomorphology-based tumour diagnostics]. PMID: 20842917 Ref: Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer. PMID: 20843314 Ref: EGFR and KRAS in colorectal cancer. PMID: 20857619 Ref: A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. PMID: 20864632 Ref: EGFR antibodies in colorectal cancer: where do they belong? PMID: 20921457 Ref: Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? PMID: 20921461 Ref: Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. PMID: 20939111 Ref: Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. PMID: 20946648 Ref: Targeted therapeutic agents for colorectal cancer. PMID: 20951919 Ref: [Current status and perspectives of biologics in the treatment of metastatic colorectal cancer]. PMID: 20954331 Ref: [Multimodality therapy of colorectal cancer]. PMID: 20967408 Ref: BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer. PMID: 20972475 Ref: Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). PMID: 21036743 Ref: Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. PMID: 21036746 Ref: Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. PMID: 21042543 Ref: Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer? PMID: 21051017 Ref: High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples. PMID: 21052001 Ref: Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. PMID: 21053280 Ref: [Two cases of colorectal cancer patients with poor performance status who had unresectable liver metastasis effectively treated by cetuximab]. PMID: 21084825 Ref: DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PMID: 21103049 Ref: Kras in metastatic colorectal cancer. PMID: 21104470 Ref: COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma. PMID: 21110880 Ref: Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. PMID: 21115922 Ref: Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? PMID: 21129611 Ref: Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. PMID: 21139621 Ref: Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer. PMID: 21151408 Ref: Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis. PMID: 21152137 Ref: Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. PMID: 21154125 Ref: Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. PMID: 21154162 Ref: Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. PMID: 21157973 Ref: Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. PMID: 21163770 Ref: Chemotherapy of metastatic colorectal cancer. PMID: 21180382 Ref: [Targeted therapies in colorectal cancer]. PMID: 21197741 Ref: [Clinical significance of BRAF mutations in colorectal cancer]. PMID: 21220223 Ref: Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists. PMID: 21299161 Ref: Combination effect of cetuximab with radiation in colorectal cancer cells. PMID: 21302618 Ref: Multiplexed Five-Color Molecular Imaging of Cancer Cells and Tumor Tissues with Carbon Nanotube Raman Tags in the Near-Infrared. PMID: 21442006 Ref: Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. PMID: 21474966 Ref: The EGFR R521K polymorphism influences the risk to develop colorectal cancer. PMID: 21896992 Ref: LNA-based PCR clamping enrichment assay for the identification of KRAS mutations. PMID: 21896996 Ref: KRAS mutation detection in Tunisian sporadic coloractal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography. PMID: 22072121 Ref: Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. PMID: 23074401 Ref: Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. PMID: 23074402 Ref: KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis. PMID: 23074403 Ref: Relating biomarkers to efficacy and the efficacy curve: a review of EGFR therapies in oncology. PMID: 29783375 |
Ref: A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. PMID: 19830388 Ref: First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). PMID: 20042346 Ref: Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense? PMID: 20070321 Ref: A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). PMID: 20204674 Ref: Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. PMID: 20473900 Ref: KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. PMID: 20563851 Ref: PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. PMID: 20571907 Ref: KRAS testing on colo-rectal carcinoma cytological imprints. PMID: 20607679 Ref: Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer. PMID: 20635387 Ref: Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. PMID: 20645028 Ref: Use of molecular markers for predicting therapy response in cancer patients. PMID: 20685042 Ref: Regulation of colon cancer cell proliferation and migration by MD-2 activity. PMID: 20699280 Ref: Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy. PMID: 20718834 Ref: Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. PMID: 20726623 Ref: All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. PMID: 20817364 Ref: EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. PMID: 20824716 Ref: Reversion-inducing cysteine-rich protein with Kazal motifs interferes with epidermal growth factor receptor signaling. PMID: 20890302 Ref: Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. PMID: 20956938 Ref: Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX. PMID: 20972872 Ref: Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death. PMID: 20980803 Ref: An in vitro chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to cetuximab. PMID: 20980824 Ref: KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. PMID: 21029218 Ref: Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens. PMID: 21030527 Ref: Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. PMID: 21080109 Ref: Chrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway. PMID: 21089180 Ref: HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. PMID: 21098338 Ref: Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. PMID: 21099348 Ref: Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. PMID: 21104178 Ref: Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells. PMID: 21109589 Ref: EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. PMID: 21109951 Ref: Tissue sampling for mutation analysis in colorectal cancer: K-ras is homogeneously distributed throughout the tumor tissue. PMID: 21109984 Ref: MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. PMID: 21118963 Ref: GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. PMID: 21156786 Ref: PI-3-Kinase inhibitors in colorectal cancer. PMID: 21158718 Ref: Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. PMID: 21161336 Ref: KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. PMID: 21163703 Ref: Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis. PMID: 21174064 Ref: Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? PMID: 21183281 Ref: Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. PMID: 21193546 Ref: Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. PMID: 21200037 Ref: The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. PMID: 21212430 Ref: Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells. PMID: 21215330 Ref: Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. PMID: 21217396 Ref: Loss of E-cadherin independently predicts the lymph node status in colorectal cancer. PMID: 21233674 Ref: Rapid detection of low-abundance K-ras mutation in stools of colorectal cancer patients using chip-based temperature gradient capillary electrophoresis. PMID: 21242956 Ref: Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy. PMID: 21255939 Ref: Anti-tumor effects of proteoglycan from Phellinus linteus by immunomodulating and inhibiting Reg IV/EGFR/Akt signaling pathway in colorectal carcinoma. PMID: 21262260 Ref: [Recent results of research on cancer of the colon, gastric cancer, sarcoma and bronchial carcinoma]. PMID: 21271476 Ref: Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging. PMID: 21272665 Ref: Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. PMID: 21273511 Ref: Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion. PMID: 21273532 Ref: Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PMID: 21283802 Ref: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. PMID: 21285991 Ref: Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan. PMID: 21286718 Ref: Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. PMID: 21286919 Ref: BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer. PMID: 21289333 Ref: Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. PMID: 21305640 Ref: A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. PMID: 21315413 Ref: Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. PMID: 21340604 Ref: Antiepidermal growth factor receptor radiosensitizers in rectal cancer. PMID: 21346551 Ref: The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. PMID: 21356164 Ref: [A case of advanced colon cancer successfully treated with cetuximab diagnosed as EGFR-positive by liver biopsy]. PMID: 21368503 Ref: Lithium reduces tumorigenic potential in response to EGF signaling in human colorectal cancer cells. PMID: 21369697 Ref: Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. PMID: 21383692 Ref: EGFR Signaling in Colorectal Carcinoma. PMID: 21403829 Ref: Molecular predictors of response to chemotherapy in colorectal cancer. PMID: 21427555 Ref: Targeted therapy in colorectal cancer: current status and future challenges. PMID: 21428886 Ref: Impact of KRAS Mutations on Management of Colorectal Carcinoma. PMID: 21437184 Ref: HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PMID: 21464950 Ref: Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). PMID: 21468552 Ref: Mutations in K-ras and epidermal growth factor receptor expression in Korean patients with stages III and IV colorectal cancer. PMID: 21474505 Ref: Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells. PMID: 21479670 Ref: Epidermal growth factor receptor targeted therapies for solid tumours. PMID: 21485758 Ref: Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series. PMID: 21498735 Ref: Amphiregulin exosomes increase cancer cell invasion. PMID: 21514161 Ref: The "cryptic" mechanism of action of glucagon-like peptide-2. PMID: 21527727 Ref: Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases. PMID: 21536390 Ref: Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. PMID: 21538846 Ref: Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models. PMID: 21554739 Ref: Cetuximab in the treatment of patients with colorectal cancer. PMID: 21557708 Ref: Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. PMID: 21558395 Ref: Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. PMID: 21559018 Ref: Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. PMID: 21573767 Ref: KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. PMID: 21575616 Ref: Panitumumab (vectibix). PMID: 21596817 Ref: Antitumor effects of a novel benzonaphthofurandione derivative (8e) on the human colon cancer cells in vitro and in vivo through cell cycle arrest accompanied with the modulation of EGFR and mTOR signaling. PMID: 21600193 Ref: Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. PMID: 21603900 Ref: Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. PMID: 21609938 Ref: Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. PMID: 21617858 Ref: EGFR genomic alterations in cancer: prognostic and predictive values. PMID: 21622099 Ref: Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. PMID: 21632860 Ref: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. PMID: 21641636 Ref: Ultraviolet irradiation can induce evasion of colon cancer cells from stimulation of epidermal growth factor. PMID: 21646361 Ref: Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. PMID: 21646616 Ref: The inhibitory effects of 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone on human colon cancer cells. PMID: 21648071 Ref: EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. PMID: 21653642 Ref: Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. PMID: 21653830 Ref: Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. PMID: 21660955 Ref: Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure? PMID: 21661405 Ref: Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. PMID: 21664646 Ref: Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. PMID: 21670084 Ref: The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. PMID: 21671463 Ref: [Colorectal cancer chemotherapy and anti-EGFR therapy]. PMID: 21677479 Ref: [Identification of K-RAS mutations in colorectal cancer patients in Israel]. PMID: 21678640 Ref: [Personalized medicine--the future is already here]. PMID: 21678641 Ref: EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. PMID: 21694725 Ref: Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. PMID: 21701884 Ref: Do all lung adenocarcinomas follow a stepwise progression? PMID: 21705107 Ref: Targeting the insulin growth factor pathway in gastrointestinal cancers. PMID: 21717907 Ref: Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells. PMID: 21722395 Ref: Function of erbB receptors and DNA-PKcs on phosphorylation of cytoplasmic and nuclear Akt at S473 induced by erbB1 ligand and ionizing radiation. PMID: 21723633 Ref: Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? PMID: 21729677 Ref: Development of molecular biomarkers in individualized treatment of colorectal cancer. PMID: 21729679 Ref: Colon cancer: a civilization disorder. PMID: 21734388 Ref: Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models. PMID: 21737635 Ref: Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. PMID: 21737652 Ref: Differential detection of KRAS mutations in codons 12 and 13 with a modified loop-hybrid (LH) mobility shift assay using an insert-type LH-generator. PMID: 21741959 Ref: Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. PMID: 21742964 Ref: [KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma]. PMID: 21751504 Ref: [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer]. PMID: 21772090 Ref: The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. PMID: 21772841 Ref: Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway. PMID: 21782788 Ref: Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. PMID: 21785539 Ref: Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. PMID: 21788356 Ref: The role of neuregulin4 and HER4 in gastrointestinal malignant lymphoma. PMID: 21805036 Ref: From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. PMID: 21810511 Ref: Predictive molecular classifiers in colorectal cancer. PMID: 21810517 Ref: [KRAS mutation test]. PMID: 21815483 Ref: Epidermal growth factor receptor mutations in colorectal cancer patients. PMID: 21829767 Ref: Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. PMID: 21837660 Ref: Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. PMID: 21859497 Ref: The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. PMID: 21868546 Ref: Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. PMID: 21874108 Ref: Expression of membranous epidermal growth factor receptor in colorectal adenocarcinoma and its correlation with clinicopathological features. PMID: 21874828 Ref: EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. PMID: 21880790 Ref: Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. PMID: 21890455 Ref: KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. PMID: 21894049 Ref: Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. PMID: 21900113 Ref: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. PMID: 21900593 Ref: [The present situation regarding postoperative adjuvant chemotherapy]. PMID: 21918334 Ref: EGFR-targeted therapy. PMID: 21925171 Ref: The significance of a group of molecular markers and clinicopathological factors in identifying colorectal liver metastasis. PMID: 21937374 Ref: [Tm analysis method using a quenching probe is a simple and rapid way to simultaneously detect KRAS and BRAF mutations]. PMID: 21942085 Ref: The effect of combining interferon-alpha and gefitinib in human colon cancer cell lines. PMID: 21942111 Ref: Bioactive properties and clinical safety of a novel milk protein peptide. PMID: 21943352 Ref: Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. PMID: 21943394 Ref: Neurotensin-induced Erk1/2 phosphorylation and growth of human colonic cancer cells are independent from growth factors receptors activation. PMID: 21945442 Ref: Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. PMID: 21949247 Ref: Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. PMID: 21961726 Ref: Epidermal growth factor receptor pathway mutations and colorectal cancer therapy. PMID: 21970483 Ref: Gene expression profile of human colon cancer cells treated with cross-reacting material 197, a diphtheria toxin non-toxic mutant. PMID: 21978696 Ref: Anti-EGFR therapy in first-line colorectal cancer. PMID: 21999123 Ref: Where now for anti-EGF receptor therapies in colorectal cancer? PMID: 21999128 Ref: Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer. PMID: 22016105 Ref: The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. PMID: 22026926 Ref: Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. PMID: 22045189 Ref: American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR. PMID: 22070864 Ref: Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer. PMID: 22074249 Ref: Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. PMID: 22117530 Ref: The nuclear epidermal growth factor receptor signaling network and its role in cancer. PMID: 22127113 Ref: [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer]. PMID: 22145213 Ref: Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model. PMID: 22171126 Ref: Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PMID: 22174910 Ref: Regulation of cysteinyl leukotriene receptor 2 expression--a potential anti-tumor mechanism. PMID: 22194989 Ref: Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. PMID: 22195963 Ref: Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer. PMID: 22199994 Ref: [Three cases of patients in their eighties who received anti-EGFR antibody mono-therapy as first-line treatment for metastatic colorectal cancer]. PMID: 22202343 Ref: KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PMID: 22216189 Ref: Epidermal growth factor receptor overexpression/amplification in adenocarcinomas arising in the gastrointestinal tract. PMID: 22217347 Ref: Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients. PMID: 22248908 Ref: Digital pathology in personalized cancer therapy. PMID: 22252751 Ref: [The role of chemotherapy and targeted antiVEGF- and antiEGFR-therapy in metastatic colorectal cancer: a case report of long-term and intensive response]. PMID: 22257237 Ref: [Phase I study of anti-EGFR monoclonal antibody (CMAB009) in patients with advanced cancer]. PMID: 22321747 Ref: [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy]. PMID: 22329297 Ref: HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. PMID: 22586650 Ref: A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. PMID: 22586653 Ref: Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond. PMID: 23480583 Ref: Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy. PMID: 24212803 Ref: Toll-like receptor 4 signaling integrates intestinal inflammation with tumorigenesis: lessons from the murine model of colitis-associated cancer. PMID: 24212947 Ref: The role of kras mutations and MSI status in diagnosis of colorectal cancer. PMID: 24834160 Ref: Colorectal cancer and NF-kappaB signaling pathway. PMID: 24834170 |
Ref: X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. PMID: 21167658 Ref: Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. PMID: 21652149 Ref: [EGFR/HER1: a target life]. PMID: 21684835 Ref: Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. PMID: 21706149 Ref: The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines. PMID: 21879255 Ref: Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice. PMID: 21913035 Ref: Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. PMID: 21924350 Ref: Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. PMID: 21925954 Ref: Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer. PMID: 21936753 Ref: Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. PMID: 21951556 Ref: BAG-1 interacts with the p50-p50 homodimeric NF-kappaB complex: implications for colorectal carcinogenesis. PMID: 21963853 Ref: Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. PMID: 21971641 Ref: Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients. PMID: 21989899 Ref: PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. PMID: 22039088 Ref: Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? PMID: 22043994 Ref: EphrinA5 suppresses colon cancer development by negatively regulating epidermal growth factor receptor stability. PMID: 22074469 Ref: Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. PMID: 22112971 Ref: Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. PMID: 22118887 Ref: Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. PMID: 22126621 Ref: Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. PMID: 22130903 Ref: No evidence for PML-RARa bcr1 fusion gene in colorectal cancer. PMID: 22167334 Ref: To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer. PMID: 22169039 Ref: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. PMID: 22173549 Ref: Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. PMID: 22189054 Ref: COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing. PMID: 22194627 Ref: Role of anti-EGFR target therapy in colorectal carcinoma. PMID: 22201852 Ref: Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. PMID: 22208484 Ref: Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. PMID: 22210086 Ref: Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. PMID: 22210091 Ref: PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. PMID: 22213822 Ref: Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. PMID: 22229245 Ref: Dietary calcium supplementation enhances efficacy but also toxicity of EGFR inhibitor therapy for colon cancer. PMID: 22231407 Ref: mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. PMID: 22262166 Ref: Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells. PMID: 22266356 Ref: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. PMID: 22270724 Ref: EGFR regulation of colon cancer stem-like cells during aging and in response to the colonic carcinogen dimethylhydrazine. PMID: 22281474 Ref: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. PMID: 22281684 Ref: Exploring biomarkers in head and neck cancer. PMID: 22281752 Ref: PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. PMID: 22285706 Ref: Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations. PMID: 22306670 Ref: KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13. PMID: 22306671 Ref: CIP2A overexpression is associated with c-Myc expression in colorectal cancer. PMID: 22310977 Ref: Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy. PMID: 22321154 Ref: [Pathologically complete response for unresectable stage IV rectal cancer using systemic chemotherapy with panitumumab - a case report]. PMID: 22333651 Ref: The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells. PMID: 22343320 Ref: Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. PMID: 22361730 Ref: Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. PMID: 22371427 Ref: Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. PMID: 22385512 Ref: DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. PMID: 22385513 Ref: Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. PMID: 22392911 Ref: Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer. PMID: 22399593 Ref: Long-term treatment of metastatic colorectal cancer with panitumumab. PMID: 22408376 Ref: Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. PMID: 22409860 Ref: Correlations between clinicopathological parameters and molecular signatures of primary tumors for patients with stage T3n0 colorectal adenocarcinomas: a single center retrospective study on 100 cases. PMID: 22414548 Ref: Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis. PMID: 22414609 Ref: Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. PMID: 22427190 Ref: Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. PMID: 22427198 Ref: Differential expression of senescence and cell death factors in non-small cell lung and colorectal tumors showing telomere attrition. PMID: 22433385 Ref: Effect of image compression and scaling on automated scoring of immunohistochemical stainings and segmentation of tumor epithelium. PMID: 22436596 Ref: A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. PMID: 22439666 Ref: Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma. PMID: 22446020 Ref: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. PMID: 22448344 Ref: Three different KRAS statuses in three synchronous colorectal cancers. PMID: 22467075 Ref: Phthalocyanine-peptide conjugates for epidermal growth factor receptor targeting. PMID: 22468711 Ref: Explaining the unexplainable: EGFR antibodies in colorectal cancer. PMID: 22473160 Ref: ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines. PMID: 22485250 Ref: Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. PMID: 22486600 Ref: Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. PMID: 22489692 Ref: Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. PMID: 22490361 Ref: Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. PMID: 22495350 Ref: Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPbeta-dependent suppression of EGFR expression. PMID: 22496619 Ref: hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. PMID: 22496927 Ref: Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. PMID: 22505231 Ref: Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer. PMID: 22517696 Ref: Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX-2 expression in intestinal epithelial cells. PMID: 22517768 Ref: Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC). PMID: 22526166 Ref: Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. PMID: 22549179 Ref: Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells. PMID: 22552366 Ref: CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. PMID: 22552741 Ref: Early FDG/PET scanning as a pharmacodynamic marker of anti-EGFR antibody activity in colorectal cancer. PMID: 22562987 Ref: Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives. PMID: 22571659 Ref: Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. PMID: 22576341 Ref: Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. PMID: 22581265 Ref: High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. PMID: 22584434 Ref: Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine. PMID: 22586043 Ref: The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. PMID: 22594497 Ref: Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. PMID: 22610356 Ref: The role of capecitabine in locally advanced rectal cancer treatment: an update. PMID: 22621694 Ref: Amphiregulin is a prognostic factor in colorectal cancer. PMID: 22641668 Ref: A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. PMID: 22643351 Ref: KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PMID: 22675430 Ref: Triplex DNA-binding proteins are associated with clinical outcomes revealed by proteomic measurements in patients with colorectal cancer. PMID: 22682314 Ref: Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target. PMID: 22694907 Ref: Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PMID: 22701615 Ref: Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. PMID: 22711167 Ref: Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. PMID: 22712795 Ref: KRAS mutant colorectal tumors: past and present. PMID: 22714415 Ref: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. PMID: 22722830 Ref: Study of molecular prognostic factors Bcl-2 and EGFR in rectal mucinous carcinomas. PMID: 22732796 Ref: Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers? PMID: 22735932 Ref: Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis. PMID: 22740969 Ref: Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. PMID: 22751462 Ref: Efficacy of EGFR inhibition is modulated by model, sex, genetic background and diet: implications for preclinical cancer prevention and therapy trials. PMID: 22761823 Ref: Alteration of EGFR spatiotemporal dynamics suppresses signal transduction. PMID: 22761867 Ref: Involvement of nuclear NHERF1 in colorectal cancer progression. PMID: 22766563 Ref: Epidermal growth factor receptor inhibits colitis-associated cancer in mice. PMID: 22772467 Ref: A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes. PMID: 22773565 Ref: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. PMID: 22773810 Ref: The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location. PMID: 22783405 Ref: Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological PMID: 22783573 Ref: Cisplatin and ultra-violet-C synergistically down-regulate receptor tyrosine kinases in human colorectal cancer cells. PMID: 22788833 Ref: Both stromal cell and colonocyte epidermal growth factor receptors control HCT116 colon cancer cell growth in tumor xenografts. PMID: 22791816 Ref: KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. PMID: 22797671 Ref: Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. PMID: 22804917 Ref: KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. PMID: 22805329 Ref: Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers. PMID: 22825001 Ref: Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. PMID: 22832932 Ref: BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition. PMID: 22842573 Ref: Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. PMID: 22845480 Ref: Molecular diagnosis on tissues and cells: how it affects training and will affect practice in the future. PMID: 22846108 Ref: The rectal cancer microRNAome--microRNA expression in rectal cancer and matched normal mucosa. PMID: 22850566 Ref: Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). PMID: 22855150 Ref: A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PMID: 22860045 Ref: [Therapeutic monoclonal antibodies in oncology]. PMID: 22863361 Ref: Study of KRAS new predictive marker in a clinical laboratory. PMID: 22865324 Ref: EGFR and PKC are involved in the activation of ERK1/2 and p90 RSK and the subsequent proliferation of SNU-407 colon cancer cells by muscarinic acetylcholine receptors. PMID: 22865467 Ref: c-Src antisense complexed with PAMAM denderimes decreases of c-Src expression and EGFR-dependent downstream genes in the human HT-29 colon cancer cell line. PMID: 22901200 Ref: [Evaluation of skin toxicity caused by cetuximab related to its clinical response]. PMID: 22902446 Ref: K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. PMID: 22909976 Ref: Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PMID: 22911782 Ref: The prognostic value of KRAS mutations in patients with colorectal cancer. PMID: 22922794 Ref: Meprinalpha transactivates the epidermal growth factor receptor (EGFR) via ligand shedding, thereby enhancing colorectal cancer cell proliferation and migration. PMID: 22923609 Ref: EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis. PMID: 22925500 Ref: Digital pathology in personalized cancer therapy. PMID: 22925795 Ref: Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. PMID: 22931052 Ref: The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines. PMID: 22935976 Ref: Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules. PMID: 22969927 Ref: Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice. PMID: 22969964 Ref: EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. PMID: 22975375 Ref: Molecular markers predict distant metastases after adjuvant chemoradiation for rectal cancer. PMID: 22981710 Ref: Mutation specific antibodies: tool or dinosaur? PMID: 23006938 Ref: Redirecting gene-modified T cells toward various cancer types using tagged antibodies. PMID: 23032741 Ref: Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. PMID: 23033949 Ref: The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience. PMID: 23052154 Ref: Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines. PMID: 23063521 Ref: The response of cancers to BRAF inhibition underscores the importance of cancer systems biology. PMID: 23074264 Ref: Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. PMID: 23075074 Ref: Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer. PMID: 23091721 Ref: Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. PMID: 23097702 Ref: Multivariate analysis of molecular indicators for postoperative liver metastasis in colorectal cancer cases. PMID: 23098501 Ref: [The change of pathology in the era of personalized medicine using the example of discordant KRAS mutational status in metastasized colorectal carcinoma]. PMID: 23111797 Ref: In vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice. PMID: 23118721 Ref: Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis. PMID: 23119029 Ref: Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients. PMID: 23125007 Ref: Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro. PMID: 23141895 Ref: Bio-imaging of colorectal cancer models using near infrared labeled epidermal growth factor. PMID: 23144978 Ref: [Predictive biomarkers for anti-EGFR antibodies]. PMID: 23152013 Ref: [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma]. PMID: 23157825 Ref: Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. PMID: 23159854 Ref: KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach. PMID: 23161231 Ref: Combined EGFR and c-Src antisense oligodeoxynucleotides encapsulated with PAMAM Denderimers inhibit HT-29 colon cancer cell proliferation. PMID: 23167414 Ref: Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. PMID: 23171437 Ref: Non-autonomous crosstalk between the Jak/Stat and Egfr pathways mediates Apc1-driven intestinal stem cell hyperplasia in the Drosophila adult midgut. PMID: 23172913 Ref: Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer. PMID: 23173730 Ref: Current status of radiosensitizing agents for the management of rectal cancer. PMID: 23176042 Ref: MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. PMID: 23178117 Ref: Epidermal growth factor receptor (EGFR) gene copy number in colorectal adenoma-carcinoma progression. PMID: 23181982 Ref: Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. PMID: 23194063 Ref: KRAS mutations and subtyping in colorectal cancer in Jordanian patients. PMID: 23205087 Ref: Circulating tumor cells in lung cancer. PMID: 23207444 Ref: Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. PMID: 23213241 Ref: Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. PMID: 23220854 Ref: Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer. PMID: 23226389 Ref: No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. PMID: 23226426 Ref: Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR. PMID: 23226727 Ref: [Anti-EGFR antibody therapy for colorectal cancer]. PMID: 23259389 Ref: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. PMID: 23259591 Ref: KRAS Testing: A Tool for the Implementation of Personalized Medicine. PMID: 23264846 Ref: Discordance between EGFR expression and clinicopathologic parameters of colorectal adenocarcinoma in Taiwan. PMID: 23282210 Ref: Regulation of amphiregulin gene expression by beta-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PMID: 23285165 Ref: Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition. PMID: 23316197 Ref: Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. PMID: 23317280 Ref: High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity. PMID: 23335937 Ref: An immunohistochemical study of EGFR expression in colorectal cancer and its correlation with lymph nodes status and tumor grade. PMID: 23798940 Ref: Increased Phospho-Keratin 8 Isoforms in Colorectal Tumors Associated with EGFR Pathway Activation and Reduced Apoptosis. PMID: 27398237 Ref: K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. PMID: 27398239 |
Ref: Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis. PMID: 22035385 Ref: Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx. PMID: 22441881 Ref: Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. PMID: 22638623 Ref: Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu PMID: 22644776 Ref: Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. PMID: 22647972 Ref: KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. PMID: 22672749 Ref: FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. PMID: 22733437 Ref: Letter to the editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation. PMID: 22752244 Ref: Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. PMID: 22762963 Ref: Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. PMID: 22797062 Ref: A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. PMID: 22798500 Ref: Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples. PMID: 22833420 Ref: Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones. PMID: 22847744 Ref: Aneuploid human colonic epithelial cells are sensitive to AICAR-induced growth inhibition through EGFR degradation. PMID: 22890317 Ref: Author's reply to: "Prognostic value of cetuximab related skintoxicity in metastatic colorectal cancer patients and its correlation with parameters of the EGFR signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group" PMID: 22930449 Ref: Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab. PMID: 22956286 Ref: Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. PMID: 22973964 Ref: Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. PMID: 22991232 Ref: Celecoxib induces proliferation and Amphiregulin production in colon subepithelial myofibroblasts, activating erk1-2 signaling in synergy with EGFR. PMID: 23010081 Ref: KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. PMID: 23015072 Ref: Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. PMID: 23053743 Ref: RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. PMID: 23065657 Ref: Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. PMID: 23083634 Ref: UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. PMID: 23102841 Ref: The usability of allele-specific PCR and reverse-hybridization assays for KRAS genotyping in Serbian colorectal cancer patients. PMID: 23108567 Ref: Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination. PMID: 23128103 Ref: Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. PMID: 23136247 Ref: KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. PMID: 23155138 Ref: Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. PMID: 23158210 Ref: Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. PMID: 23161513 Ref: Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. PMID: 23166225 Ref: Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines. PMID: 23188824 Ref: In vivo molecular imaging of epidermal growth factor receptor in patients with colorectal neoplasia using confocal laser endomicroscopy. PMID: 23220286 Ref: HER3 overexpression and survival in solid tumors: a meta-analysis. PMID: 23221996 Ref: High-sensitivity epidermal growth factor receptor immunostaining for colorectal carcinomas, compared with EGFR PharmDx: a study of diagnostic accuracy. PMID: 23236539 Ref: Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. PMID: 23251002 Ref: Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. PMID: 23255930 Ref: Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. PMID: 23265711 Ref: KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review. PMID: 23274581 Ref: Prognostic significance and targeting of HER family in colorectal cancer. PMID: 23276932 Ref: Effect of genomic instability and mutations on the signaling pathways in colon cancer cells. PMID: 23277013 Ref: Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. PMID: 23281225 Ref: Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. PMID: 23281932 Ref: Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. PMID: 23297721 Ref: Cohypermethylation of p14 in combination with CADM1 or DCC as a recurrence-related prognostic indicator in stage I esophageal squamous cell carcinoma. PMID: 23310950 Ref: Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. PMID: 23316969 Ref: Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. PMID: 23322207 Ref: Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation. PMID: 23328545 Ref: Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. PMID: 23335047 Ref: Chromosome 16q loss--a genetic key to the understanding of breast carcinogenesis. PMID: 23348384 Ref: Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditions. PMID: 23355875 Ref: Targeted therapies in colorectal cancer-an integrative view by PPPM. PMID: 23356214 Ref: Synthesis and application of a novel cysteine-based DTPA-NCS for targeted radioimmunotherapy. PMID: 23357082 Ref: Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. PMID: 23368856 Ref: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. PMID: 23374602 Ref: High expression of epidermal growth factor receptor might predict poor survival in patients with colon cancer: a meta-analysis. PMID: 23387315 Ref: Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. PMID: 23400679 Ref: KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. PMID: 23404247 Ref: Everolimus in colorectal cancer. PMID: 23406528 Ref: Function and mode of action of cytohesins in the epidermal growth factor pathway in colorectal cancer cells. PMID: 23420529 Ref: Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. PMID: 23420587 Ref: Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome. PMID: 23429196 Ref: Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? PMID: 23429431 Ref: EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PMID: 23441167 Ref: Telmisartan inhibits cell proliferation by blocking nuclear translocation of ProHB-EGF C-terminal fragment in colon cancer cells. PMID: 23451083 Ref: The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. PMID: 23451330 Ref: Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas. PMID: 23454247 Ref: Berberine inhibits proliferation and down-regulates epidermal growth factor receptor through activation of Cbl in colon tumor cells. PMID: 23457600 Ref: Proteogenomic analysis of human colon carcinoma cell lines LIM1215, LIM1899, and LIM2405. PMID: 23458625 Ref: EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. PMID: 23459231 Ref: Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer. PMID: 23465274 Ref: The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. PMID: 23473612 Ref: The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer. PMID: 23478150 Ref: The KRAS StripAssay for detection of KRAS mutation in Egyptian patients with colorectal cancer (CRC): a pilot study. PMID: 23499205 Ref: Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. PMID: 23499207 Ref: Salmonella infection upregulates the leaky protein claudin-2 in intestinal epithelial cells. PMID: 23505542 Ref: Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. PMID: 23518595 Ref: Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. PMID: 23523951 Ref: [Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience]. PMID: 23528169 Ref: Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. PMID: 23528430 Ref: EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. PMID: 23534780 Ref: TGF-Beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis. PMID: 23536895 Ref: A new microarray substrate for ultra-sensitive genotyping of KRAS and BRAF gene variants in colorectal cancer. PMID: 23536897 Ref: Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. PMID: 23538047 Ref: Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances Susceptibility to Therapeutic Regimens. PMID: 23544170 Ref: The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-lin PMID: 23547747 Ref: High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. PMID: 23548132 Ref: Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PMID: 23555746 Ref: Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine. PMID: 23560377 Ref: Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer. PMID: 23565769 Ref: Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature. PMID: 23569465 Ref: Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients. PMID: 23572025 Ref: [Biomarkers in solid tumors]. PMID: 23573523 Ref: Analysis of the mRNA expression of chemotherapy-related genes in colorectal carcinoma using the danenberg tumor profile method. PMID: 23577026 Ref: Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met. PMID: 23580180 Ref: In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer. PMID: 23580409 Ref: Effect of microformulation on the bioactivity of an anthocyanin-rich bilberry pomace extract ( Vaccinium myrtillus L.) in vitro. PMID: 23581244 Ref: Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. PMID: 23599147 Ref: KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. PMID: 23606169 Ref: Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. PMID: 23613671 Ref: Role of beta4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. PMID: 23617461 Ref: Cholinergic muscarinic receptor activation augments murine intestinal epithelial cell proliferation and tumorigenesis. PMID: 23617763 Ref: Allele Frequencies of the Epidermal Growth Factor Receptors Polymorphism R521K in Colorectal Cancer Patients and Healthy Subjects Indicate a Risk-Reducing Effect of K521 in Syrian Population. PMID: 23626956 Ref: Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. PMID: 23633926 Ref: Personalized cancer treatment and the myth of KRAS wild-type colon tumors. PMID: 23636143 Ref: Role of targeted agents in metastatic colorectal cancer. PMID: 23645285 Ref: Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. PMID: 23645782 Ref: BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. PMID: 23650027 Ref: Companion biomarkers: paving the pathway to personalized treatment for cancer. PMID: 23656699 Ref: Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. PMID: 23657789 Ref: A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PMID: 23671647 Ref: Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells. PMID: 23677180 Ref: Design, synthesis and biological evaluation of 2-mercapto-3-phenethylquinazoline bearing anilide fragments as potential antitumor agents: molecular docking study. PMID: 23683592 Ref: Right drug for the right patient: hurdles and the path forward in colorectal cancer. PMID: 23714474 Ref: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. PMID: 23725851 Ref: KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort. PMID: 23729268 Ref: Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. PMID: 23729478 Ref: Induction of apoptosis and the regulation of ErbB signaling by laminarin in HT-29 human colon cancer cells. PMID: 23739740 Ref: Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. PMID: 23741067 Ref: Alternate dosing of cetuximab for patients with metastatic colorectal cancer. PMID: 23745159 Ref: Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling. PMID: 23754208 Ref: Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. PMID: 23757356 Ref: Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. PMID: 23763264 Ref: Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. PMID: 23792568 Ref: Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine. PMID: 23792572 Ref: Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy. PMID: 23800895 Ref: Clinical significance of VEGFR-2 and (1)(8)F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy. PMID: 23801169 Ref: Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. PMID: 23806981 Ref: MicroRNAs targeting EGFR signalling pathway in colorectal cancer. PMID: 23817698 Ref: Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells. PMID: 23824671 Ref: Layered signaling regulatory networks analysis of gene expression involved in malignant tumorigenesis of non-resolving ulcerative colitis via integration of cross-study microarray profiles. PMID: 23825635 Ref: Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer. PMID: 23832066 Ref: Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. PMID: 23849768 Ref: [Effect of magnesium supplementation on early-stage hypomagnesemia in patients treated with cetuximab]. PMID: 23863731 Ref: Loss of RASSF1A expression in colorectal cancer and its association with K-ras status. PMID: 23865079 Ref: TNFalpha and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. PMID: 23866118 Ref: Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. PMID: 23867504 Ref: Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer. PMID: 23871153 Ref: Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy. PMID: 23874486 Ref: Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. PMID: 23876834 Ref: Exploring pyrimidine-substituted curcumin analogues: design, synthesis and effects on EGFR signaling. PMID: 23880083 Ref: [Correlation between the presence of Kras mutation and the presence of the proteins epiregulin and amphiregulin in colon cancer tissue]. PMID: 23885463 Ref: Proteinuria as a risk factor for mortality in patients with colorectal cancer. PMID: 23918569 Ref: Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PMID: 23922754 Ref: Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system. PMID: 23926437 Ref: EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. PMID: 23930206 Ref: Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. PMID: 23934607 Ref: Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience. PMID: 23935912 Ref: Targeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibody. PMID: 23937913 Ref: 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. PMID: 23950653 Ref: Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells. PMID: 23959460 Ref: Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. PMID: 23960095 Ref: [Association of epithermal growth factor receptor expression and its downstream gene mutation status with radiosensitivity of colorectal carcinoma cell lines in vitro]. PMID: 23980047 Ref: [Expression of molecular markers detected by immunohistochemistry and risk of lymph node metastasis in stage T1 and T2 colorecrectal cancers]. PMID: 23985256 Ref: Functional expression of the voltage-gated Na(+)-channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells. PMID: 23986482 Ref: The role of epidermal growth factor receptor in cancer metastasis and microenvironment. PMID: 23986907 Ref: Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma. PMID: 23991179 Ref: Status of targeted therapies in the adjuvant treatment of colon cancer. PMID: 23997937 Ref: Markers of resistance to anti-EGFR therapy in colorectal cancer. PMID: 23997942 Ref: K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011. PMID: 23999847 Ref: Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. PMID: 24020794 Ref: Combination of the EGFR tyrosine kinase inhibitor AG1478 and 5-FU: no synergistic effect on EGFR phosphorylation, cell proliferation and apoptosis induction. PMID: 24023306 Ref: Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. PMID: 24023327 Ref: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. PMID: 24024839 Ref: Multi-kinase modulation for colon cancer therapy. PMID: 24025253 Ref: The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. PMID: 24025416 Ref: Evaluation of the immune factors in the tumor environment before and after the treatment of cetuximab combined with chemotherapy. PMID: 24028754 Ref: The cannabinoid WIN 55,212-2 decreases specificity protein transcription factors and the oncogenic cap protein eIF4E in colon cancer cells. PMID: 24030632 Ref: The role of tumor markers and biomarkers in colorectal cancer. PMID: 24050544 Ref: The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. PMID: 24050852 Ref: Combined effects of C225 and 125-iodine seed radiation on colorectal cancer cells. PMID: 24053278 Ref: Epidermal growth factor receptor: pathway, therapies, and pipeline. PMID: 24054705 Ref: K-ras gene mutation status in colorectal cancer: comparative analysis of pyrosequencing and PCR-RFLP. PMID: 24068405 Ref: Claudin-3 overexpression increases the malignant potential of colorectal cancer cells: roles of ERK1/2 and PI3K-Akt as modulators of EGFR signaling. PMID: 24069372 Ref: Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. PMID: 24086949 Ref: Novel oncoprotein EPS8: a new target for anticancer therapy. PMID: 24106906 Ref: BRAF V600E is a determinant of sensitivity to proteasome inhibitors. PMID: 24107445 Ref: Increased TGF-alpha as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. PMID: 24122793 Ref: HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. PMID: 24146218 Ref: Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies. PMID: 24151349 Ref: Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway. PMID: 24152305 Ref: [Clinical-pathological features and gene profile in colorectal cancer]. PMID: 24152396 Ref: Morphological and immunohistochemical criteria of tissue response to radiotherapy in rectal cancer. PMID: 24157103 Ref: Emerging treatments in recurrent and metastatic colorectal cancer. PMID: 24158967 Ref: Multigene assays in metastatic colorectal cancer. PMID: 24158971 Ref: EGF receptor and COX-1/COX-2 enzyme proteins as related to corresponding mRNAs in human per-operative biopsies of colorectal cancer. PMID: 24171795 Ref: Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. PMID: 24180698 Ref: [A case study of stable disease after hepatic arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable hepatic metastases of colon cancer]. PMID: 24196078 Ref: Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. PMID: 24200637 Ref: Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. PMID: 24204198 Ref: Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prognosis in colorectal cancer. PMID: 24204699 Ref: Computational modeling of an epidermal growth factor receptor single-mutation resistance to cetuximab in colorectal cancer treatment. PMID: 24219403 Ref: Predicting skin toxicity according to EGFR polymorphisms in patients with colorectal cancer receiving antibody against EGFR. PMID: 24222141 Ref: Translating genomics in cancer care. PMID: 24225968 Ref: Personalized treatment for advanced colorectal cancer: KRAS and beyond. PMID: 24294007 Ref: Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. PMID: 24298448 Ref: NEDD4L is downregulated in colorectal cancer and inhibits canonical WNT signaling. PMID: 24312311 Ref: Not all antibodies are equal. PMID: 24317328 Ref: The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. PMID: 24330663 Ref: Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PMID: 24339949 Ref: Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. PMID: 24364033 Ref: [Outcomes of patients with small bowel carcinoma treated with appropriate chemotherapy selected on the basis of genetic analysis findings]. PMID: 24393898 Ref: [A case of advanced colorectal carcinoma with aggressively growing liver metastases successfully managed with the induction of cetuximab single-agent therapy]. PMID: 24393994 Ref: Functions and Regulation of the PTEN Gene in Colorectal Cancer. PMID: 24475377 Ref: [The frequency and spectrum of KRAS mutations in metastatic colorectal cancer]. PMID: 24624786 Ref: Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab. PMID: 24649163 Ref: Clinical implications of BRAF mutation test in colorectal cancer. PMID: 24834238 Ref: Different frequency of epidermal growth factor rs76189946 polymorphism genotype in an Iranian colorectal cancer. PMID: 24834285 Ref: Adjuvant therapy of stage III colon cancer. PMID: 25841497 Ref: Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain-A case series. PMID: 29913887 |
Ref: Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. PMID: 23296156 Ref: Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. PMID: 23493335 Ref: Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. PMID: 23568716 Ref: Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited? PMID: 23588415 Ref: Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity. PMID: 23644655 Ref: The molecular rationale of Src inhibition in colorectal carcinomas. PMID: 23733480 Ref: Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. PMID: 23817974 Ref: Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. PMID: 23852704 Ref: Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met. PMID: 23900501 Ref: Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line. PMID: 23917393 Ref: Options for metastatic colorectal cancer beyond the second line of treatment. PMID: 23954144 Ref: Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. PMID: 23959273 Ref: KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. PMID: 24022727 Ref: Clinical relevance of KRAS mutations in codon 13: Where are we? PMID: 24051306 Ref: miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. PMID: 24098024 Ref: Rectal cancer: dynamic contrast-enhanced MRI correlates with lymph node status and epidermal growth factor receptor expression. PMID: 24127411 Ref: KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. PMID: 24136682 Ref: Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling. PMID: 24166502 Ref: Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. PMID: 24170544 Ref: AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. PMID: 24170546 Ref: The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. PMID: 24184540 Ref: The role of tumor markers and biomarkers in colorectal cancer. PMID: 24195503 Ref: A PNA-mediated clamping PCR for routine detection of KRAS mutations in colorectal carcinoma. PMID: 24242294 Ref: Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. PMID: 24262587 Ref: The ErbB/HER family of protein-tyrosine kinases and cancer. PMID: 24269963 Ref: EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. PMID: 24281417 Ref: Palliative treatment of metastatic colorectal cancer: what is the optimal approach? PMID: 24293074 Ref: KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. PMID: 24331409 Ref: Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. PMID: 24335920 Ref: Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. PMID: 24351336 Ref: Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. PMID: 24390240 Ref: Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer. PMID: 24403498 Ref: [Clinical application of next-generation sequencing technologies to achieve cancer precision medicine]. PMID: 24423944 Ref: When to screen and not to screen. PMID: 24424112 Ref: Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy. PMID: 24427772 Ref: Is biomarker research advancing in the era of personalized medicine for head and neck cancer? PMID: 24442754 Ref: Preparation of clinical-grade (89) Zr-panitumumab as a positron emission tomography biomarker for evaluating epidermal growth factor receptor-targeted therapy. PMID: 24448743 Ref: MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance. PMID: 24454732 Ref: Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer. PMID: 24458108 Ref: Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status. PMID: 24467518 Ref: Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. PMID: 24496456 Ref: Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. PMID: 24500024 Ref: SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. PMID: 24503755 Ref: Melting curve analysis for mutations of EGFR and KRAS. PMID: 24510990 Ref: The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67. PMID: 24516696 Ref: Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-alpha: impact on gastrointestinal cancers driven by secondary bile acids. PMID: 24520077 Ref: Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients? PMID: 24520223 Ref: Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma. PMID: 24523613 Ref: KRAS mutations: analytical considerations. PMID: 24534449 Ref: Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. PMID: 24553387 Ref: Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. PMID: 24556630 Ref: KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. PMID: 24558511 Ref: EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell carcinoids of the appendix. PMID: 24560515 Ref: Can we accurately report PTEN status in advanced colorectal cancer? PMID: 24564252 Ref: Adenomatous polyposis coli determines sensitivity to the EGFR tyrosine kinase inhibitor gefitinib in colorectal cancer cells. PMID: 24573033 Ref: RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. PMID: 24582914 Ref: Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib. PMID: 24588073 Ref: KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations? PMID: 24594115 Ref: Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). PMID: 24595526 Ref: EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. PMID: 24595598 Ref: [Perspective of personalized (precise) cancer therapy based on predictive biomarkers]. PMID: 24597345 Ref: [The brand new trend of colorectal carcinoma pathology]. PMID: 24597350 Ref: [Use of antibodies for colorectal cancer chemotherapy]. PMID: 24597358 Ref: Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. PMID: 24609222 Ref: Cytohesins/ARNO: the function in colorectal cancer cells. PMID: 24618737 Ref: Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. PMID: 24621249 Ref: PIK3CA in Colorectal Cancer. PMID: 24624362 Ref: Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer. PMID: 24626880 Ref: ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. PMID: 24634416 Ref: Analysis of KRAS mutations in cases of metastatic colorectal cancer at a single institution in Tochigi, Japan. PMID: 24642668 Ref: A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. PMID: 24643470 Ref: HD chromoendoscopy coupled with DNA mass spectrometry profiling identifies somatic mutations in microdissected human proximal aberrant crypt foci. PMID: 24651453 Ref: Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. PMID: 24659028 Ref: Highly sensitive KRAS mutation detection from formalin-fixed paraffin-embedded biopsies and circulating tumour cells using wild-type blocking polymerase chain reaction and Sanger sequencing. PMID: 24664550 Ref: VPAC1 overexpression is associated with poor differentiation in colon cancer. PMID: 24671823 Ref: Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PMID: 24676216 Ref: Transphosphorylation of EGFR at Y845 plays an important role in its autophosphorylation and kinase activity. PMID: 24677053 Ref: Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial. PMID: 24682464 Ref: Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. PMID: 24685132 Ref: Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. PMID: 24685572 Ref: Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PMID: 24691006 Ref: COX2 inhibitor NS398 reduces HT-29 cell invasiveness by modulating signaling pathways mediated by EGFR and HIF1-alpha. PMID: 24692712 Ref: Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases. PMID: 24696747 Ref: The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study. PMID: 24700299 Ref: Exploring better strategies for EGFR antibodies in colon cancer. PMID: 24703530 Ref: P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer. PMID: 24708484 Ref: Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells. PMID: 24714091 Ref: Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice. PMID: 24720806 Ref: Resistance to irinotecan (CPT-11) activates epidermal growth factor receptor/nuclear factor kappa B and increases cellular metastasis and autophagy in LoVo colon cancer cells. PMID: 24726344 Ref: Successes and limitations of targeted cancer therapy in colon cancer. PMID: 24727985 Ref: MFAP3L activation promotes colorectal cancer cell invasion and metastasis. PMID: 24735981 Ref: Expression profiling using a cDNA array and immunohistochemistry for the extracellular matrix genes FN-1, ITGA-3, ITGB-5, MMP-2, and MMP-9 in colorectal carcinoma progression and dissemination. PMID: 24737953 Ref: Targeting EGFR in colorectal cancer: beyond KRAS exon 2. PMID: 24739895 Ref: Clinical applications using digital PCR. PMID: 24740231 Ref: The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies. PMID: 24758538 Ref: Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PMID: 24760019 Ref: Panitumumab safety for treating colorectal cancer. PMID: 24766434 Ref: Real-time bidirectional pyrophosphorolysis-activated polymerization for quantitative detection of somatic mutations. PMID: 24769870 Ref: SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1. PMID: 24775912 Ref: c-Src drives intestinal regeneration and transformation. PMID: 24788409 Ref: Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. PMID: 24788807 Ref: EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules. PMID: 24792576 Ref: The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. PMID: 24793846 Ref: BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. PMID: 24798160 Ref: Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. PMID: 24799053 Ref: Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. PMID: 24800948 Ref: MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine. PMID: 24807584 Ref: Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. PMID: 24811491 Ref: Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. PMID: 24812410 Ref: Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis. PMID: 24815445 Ref: Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer? PMID: 24819099 Ref: Targeting CD137 enhances the efficacy of cetuximab. PMID: 24837434 Ref: Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation. PMID: 24839940 Ref: A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests. PMID: 24844134 Ref: LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy. PMID: 24845030 Ref: Ras in digestive oncology: from molecular biology to clinical implications. PMID: 24849046 Ref: [BRAF gene mutation in wild-type KRAS patients with colorectal cancers]. PMID: 24861115 Ref: Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay. PMID: 24863805 Ref: Design and synthesis of quinazolinone tagged acridones as cytotoxic agents and their effects on EGFR tyrosine kinase. PMID: 24866341 Ref: Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PMID: 24874286 Ref: Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. PMID: 24876732 Ref: The prognostic value of the Na(+)/ H(+) exchanger regulatory factor 1 (NHERF1) protein in cancer. PMID: 24878819 Ref: Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array. PMID: 24884535 Ref: Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. PMID: 24885062 Ref: Up-regulation of CNDP2 facilitates the proliferation of colon cancer. PMID: 24885395 Ref: Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Srcmediated phosphorylation of EGF receptor tyrosine kinase. PMID: 24890449 Ref: Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis. PMID: 24890702 Ref: An unconventional KITENIN/ErbB4-mediated downstream signal of EGF upregulates c-Jun and the invasiveness of colorectal cancer cells. PMID: 24893630 Ref: Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. PMID: 24894453 Ref: Mutational and expressional analysis of ERBB3 gene in common solid cancers. PMID: 24909266 Ref: Acquired resistance to EGFR-targeted therapies in colorectal cancer. PMID: 24913799 Ref: Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. PMID: 24916545 Ref: TGFalpha and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. PMID: 24916700 Ref: A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. PMID: 24916771 Ref: [The combination of neoadjuvant chemoradiotherapy and epidermal growth factor receptor inhibitors in the treatment of rectal adenocarcinoma]. PMID: 24918274 Ref: Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. PMID: 24922677 Ref: ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. PMID: 24928736 Ref: Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. PMID: 24940619 Ref: Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. PMID: 24942275 Ref: Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. PMID: 24947902 Ref: [Sensitivity study on preoperative individual concomitant radiochemotherapy for rectal cancer]. PMID: 24953363 Ref: Efficacy of cetuximab in metastatic colon cancer - case report. PMID: 24956345 Ref: Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. PMID: 24960403 Ref: ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. PMID: 24970817 Ref: Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases. PMID: 24983372 Ref: Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy. PMID: 24985058 Ref: MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. PMID: 24986519 Ref: Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations. PMID: 24990411 Ref: RAS testing of colorectal carcinoma-a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. PMID: 24996433 Ref: Adenoma and carcinoma components in colonic tumors show discordance for KRAS mutation. PMID: 24998492 Ref: beta1, 4-N-acetylgalactosaminyltransferase III modulates cancer stemness through EGFR signaling pathway in colon cancer cells. PMID: 25003232 Ref: Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. PMID: 25004944 Ref: Comparison of K-ras mutations in lung, colorectal and gastric cancer. PMID: 25013470 Ref: Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells. PMID: 25016642 Ref: Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity. PMID: 25017791 Ref: Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer. PMID: 25027205 Ref: Clinical significance of GAB2, a scaffolding/docking protein acting downstream of EGFR in human colorectal cancer. PMID: 25029990 Ref: SKLB-287, anovel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antitumor activity in LoVo colorectal tumor model. PMID: 25030434 Ref: Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients. PMID: 25032217 Ref: Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer. PMID: 25052499 Ref: Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition. PMID: 25053989 Ref: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. PMID: 25057166 Ref: An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis. PMID: 25057314 Ref: Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. PMID: 25073438 Ref: Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. PMID: 25074246 Ref: Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. PMID: 25083765 Ref: Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PMID: 25090459 Ref: Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. PMID: 25110411 Ref: Epidermal growth factor stimulates nuclear factor-kappaB activation and heme oxygenase-1 expression via c-Src, NADPH oxidase, PI3K, and Akt in human colon cancer cells. PMID: 25122478 Ref: In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. PMID: 25131935 Ref: Variable NF-kappaB pathway responses in colon cancer cells treated with chemotherapeutic drugs. PMID: 25134433 Ref: Paracrine network: another step in the complexity of resistance to EGFR blockade? PMID: 25139340 Ref: Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations. PMID: 25158139 Ref: Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. PMID: 25164765 Ref: The ethanolic extract of bark from Salix aegyptiaca L. inhibits the metastatic potential and epithelial to mesenchymal transition of colon cancer cell lines. PMID: 25175673 Ref: A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. PMID: 25183481 Ref: EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells. PMID: 25198428 Ref: The concentrations of EGFR, LRG1, ITIH4, and F5 in serum correlate with the number of colonic adenomas in ApcPirc/+ rats. PMID: 25200834 Ref: The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. PMID: 25210463 Ref: The renin-angiotensin system mediates EGF receptor-vitamin d receptor cross-talk in colitis-associated colon cancer. PMID: 25212605 Ref: PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis. PMID: 25260023 Ref: Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma. PMID: 25261371 Ref: High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma. PMID: 25262986 Ref: KRAS and BRAF mutational status in colon cancer from Albanian patients. PMID: 25267307 Ref: Overexpression of the ITGAV gene is associated with progression and spread of colorectal cancer. PMID: 25275062 Ref: Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. PMID: 25287912 Ref: Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis. PMID: 25288497 Ref: Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. PMID: 25293556 Ref: Iro/IRX transcription factors negatively regulate Dpp/TGF-beta pathway activity during intestinal tumorigenesis. PMID: 25296644 Ref: The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling. PMID: 25301722 Ref: Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing. PMID: 25313182 Ref: Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer. PMID: 25321193 Ref: Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. PMID: 25324142 Ref: Somatic mutations of the HER2 in metastatic breast cancer. PMID: 25326805 Ref: Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. PMID: 25349306 Ref: Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. PMID: 25349424 Ref: Targeting cytosolic phospholipase A2 alpha in colorectal cancer cells inhibits constitutively activated protein kinase B (AKT) and cell proliferation. PMID: 25365190 Ref: Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients. PMID: 25382208 Ref: Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. PMID: 25389372 Ref: Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. PMID: 25392179 Ref: Synthetic genistein glycosides inhibiting EGFR phosphorylation enhance the effect of radiation in HCT 116 colon cancer cells. PMID: 25401399 Ref: Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer. PMID: 25416285 Ref: c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation. PMID: 25427200 Ref: Isolating EGFR Overexpressing Carcinoma Cells from Human Whole Blood by Bio-Ferrography. PMID: 25447785 Ref: Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. PMID: 25453078 Ref: Bisphosphonates inactivate human EGFRs to exert antitumor actions. PMID: 25453081 Ref: Down-regulation of sphingosine kinase 2 (SphK2) increases the effects of all-trans-retinoic acid (ATRA) on colon cancer cells. PMID: 25455157 Ref: Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes. PMID: 25458604 Ref: The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. PMID: 25474137 Ref: Epidermal growth factor receptor gene expression evaluation in colorectal cancer patients. PMID: 25494138 Ref: The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. PMID: 25525412 Ref: Surgical procedures and postsurgical tissue processing significantly affect expression of genes and EGFR-pathway proteins in colorectal cancer tissue. PMID: 25526028 Ref: EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. PMID: 25535899 Ref: Management of colorectal cancer. PMID: 25580262 Ref: Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. PMID: 25594061 Ref: Molecular pathology of colorectal cancer. PMID: 25693079 Ref: Comparison analysis in synchronous and metachronous metastatic colorectal cancer based on microarray expression profile. PMID: 25699354 Ref: [A case of postoperative colon cancer with peritoneal dissemination in which a long-term response was achieved using panitumumab maintenance therapy]. PMID: 25731301 Ref: [Mixed adenoneuroendocrine carcinoma with multiple liver metastases successfully treated by cetuximab/CPT-11 chemotherapy followed by curative resection - a case report]. PMID: 25731451 Ref: PMID: 25905152 Ref: EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivatives. PMID: 26417284 Ref: Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. PMID: 28548075 |
Ref: Correlation of dynamic contrast-enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: Preliminary results. PMID: 24375840 Ref: Molecular therapy of colorectal cancer: progress and future directions. PMID: 24420815 Ref: A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. PMID: 24469059 Ref: Structure-based drug design and biological evaluation of 2-acetamidobenzothiazole derivative as EGFR kinase inhibitor. PMID: 24601650 Ref: Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. PMID: 24806288 Ref: KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. PMID: 24889488 Ref: EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer. PMID: 25026457 Ref: Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. PMID: 25248381 Ref: MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients. PMID: 25256312 Ref: KRAS mutation status impacts diagnosis and treatment decision in a patient with two colon tumours: a case report. PMID: 25313410 Ref: Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. PMID: 25326806 Ref: Nrdp1 inhibits metastasis of colorectal cancer cells by EGFR signaling-dependent MMP7 modulation. PMID: 25330950 Ref: Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer. PMID: 25366420 Ref: Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. PMID: 25373533 Ref: Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. PMID: 25378536 Ref: Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. PMID: 25383957 Ref: Serial in vivo imaging using a fluorescence probe allows identification of tumor early response to cetuximab immunotherapy. PMID: 25397907 Ref: The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective? PMID: 25400031 Ref: Heterogeneous DNA methylation contributes to tumorigenesis through inducing the loss of coexpression connectivity in colorectal cancer. PMID: 25407423 Ref: Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer. PMID: 25410095 Ref: Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. PMID: 25412235 Ref: Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping? PMID: 25420993 Ref: Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. PMID: 25424197 Ref: Integrating systemic and surgical approaches to treating metastatic colorectal cancer. PMID: 25444476 Ref: Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. PMID: 25445327 Ref: Tissue-specific selection of optimal reference genes for expression analysis of anti-cancer drug-related genes in tumor samples using quantitative real-time RT-PCR. PMID: 25445497 Ref: Biomarkers for personalized oncology: recent advances and future challenges. PMID: 25468140 Ref: Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PMID: 25472647 Ref: In vivo molecular mapping of the tumor microenvironment in an azoxymethane-treated mouse model of colon carcinogenesis. PMID: 25487746 Ref: Isolating epidermal growth factor receptor overexpressing carcinoma cells from human whole blood by bio-ferrography. PMID: 25491065 Ref: MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. PMID: 25503932 Ref: Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. PMID: 25514114 Ref: Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. PMID: 25532759 Ref: Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. PMID: 25542231 Ref: Examination of HER3 targeting in cancer using monoclonal antibodies. PMID: 25564668 Ref: KRAS mutation analysis by PCR: a comparison of two methods. PMID: 25568935 Ref: Icotinib hydrochloride enhances the effect of radiotherapy by affecting DNA repair in colorectal cancer cells. PMID: 25572529 Ref: Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients. PMID: 25572811 Ref: Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. PMID: 25589620 Ref: Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. PMID: 25589621 Ref: Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. PMID: 25589625 Ref: Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases. PMID: 25589885 Ref: Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. PMID: 25593032 Ref: Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. PMID: 25595386 Ref: HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver. PMID: 25601452 Ref: A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum. PMID: 25604134 Ref: TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. PMID: 25608838 Ref: KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. PMID: 25609577 Ref: Fabrication of high specificity hollow mesoporous silica nanoparticles assisted by Eudragit for targeted drug delivery. PMID: 25617610 Ref: Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer. PMID: 25622824 Ref: Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. PMID: 25623215 Ref: Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. PMID: 25628445 Ref: IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. PMID: 25632036 Ref: Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. PMID: 25637035 Ref: Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. PMID: 25639985 Ref: External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. PMID: 25657200 Ref: Molecular markers predictive of chemotherapy response in colorectal cancer. PMID: 25663616 Ref: EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. PMID: 25663927 Ref: Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. PMID: 25666296 Ref: Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. PMID: 25673558 Ref: Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. PMID: 25673644 Ref: Direct correlation between double K-RAS mutation and mucinous carcinoma. A case report. PMID: 25675084 Ref: Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. PMID: 25679409 Ref: Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia. PMID: 25684939 Ref: The neoadjuvant treatment of rectal cancer: a review. PMID: 25691086 Ref: Heterozygous deletion of ATG5 in Apc(Min/+) mice promotes intestinal adenoma growth and enhances the antitumor efficacy of interferon-gamma. PMID: 25695667 Ref: Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. PMID: 25695927 Ref: Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. PMID: 25704501 Ref: Nexavar/Stivarga and viagra interact to kill tumor cells. PMID: 25704960 Ref: KRAS mutation screening by chip-based DNA hybridization--a further step towards personalized oncology. PMID: 25706807 Ref: Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. PMID: 25712343 Ref: AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. PMID: 25714871 Ref: Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. PMID: 25742472 Ref: [A successful multimodality therapy for a case of recurrent rectal cancer with KRAS mutation]. PMID: 25743147 Ref: An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis. PMID: 25746002 Ref: Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. PMID: 25750328 Ref: Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. PMID: 25756961 Ref: LRIG1 extracellular domain: structure and function analysis. PMID: 25765764 Ref: B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches. PMID: 25774859 Ref: KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. PMID: 25778307 Ref: Targeted therapy in first line treatment of RAS wild type colorectal cancer. PMID: 25780283 Ref: MITF Modulates Therapeutic Resistance through EGFR Signaling. PMID: 25789707 Ref: Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. PMID: 25800101 Ref: Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. PMID: 25815366 Ref: Colorectal cancer drug target prediction using ontology-based inference and network analysis. PMID: 25818893 Ref: Eprobe-mediated screening system for somatic mutations in the KRAS locus. PMID: 25823645 Ref: Histochemical and immunohistochemical evidence of tumor heterogeneity in colorectal cancer. PMID: 25826503 Ref: Review of systemic therapies for locally advanced and metastatic rectal cancer. PMID: 25830038 Ref: CCR 20th Anniversary commentary: in search of cetuximab's first indication-combination therapy with irinotecan in colorectal cancer. PMID: 25833307 Ref: Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris. PMID: 25834345 Ref: KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR. PMID: 25835782 Ref: Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. PMID: 25838391 Ref: VEGF and dual-EGFR inhibition in colorectal cancer. PMID: 25845022 Ref: [Accumulation of p53 protein and overexpression of the HER3 receptor in colorectal cancer]. PMID: 25847737 Ref: RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions. PMID: 25859555 Ref: A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. PMID: 25861837 Ref: Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients. PMID: 25889931 Ref: [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. PMID: 25899481 Ref: Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers. PMID: 25920435 Ref: NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels. PMID: 25922362 Ref: The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. PMID: 25926053 Ref: MiR-497 promotes metastasis of colorectal cancer cells through Nrdp1 inhibition. PMID: 25926384 Ref: KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. PMID: 25933688 Ref: A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. PMID: 25936694 Ref: Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. PMID: 25943333 Ref: Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. PMID: 25943534 Ref: RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. PMID: 25944693 Ref: Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment. PMID: 25944804 Ref: Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PMID: 25954997 Ref: Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. PMID: 25962717 Ref: Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients. PMID: 25965827 Ref: Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. PMID: 25973297 Ref: A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases. PMID: 25973306 Ref: The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. PMID: 25975986 Ref: Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. PMID: 25979833 Ref: KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer? PMID: 25983749 Ref: Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation. PMID: 25987127 Ref: Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer. PMID: 25990448 Ref: Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. PMID: 25993166 Ref: Biologic therapies in colorectal cancer: indications and contraindications. PMID: 25993173 Ref: Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. PMID: 25998052 Ref: RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. PMID: 26005835 Ref: Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13. PMID: 26026309 Ref: Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. PMID: 26027741 Ref: Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. PMID: 26029459 Ref: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. PMID: 26030179 Ref: Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. PMID: 26034219 Ref: Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations. PMID: 26035720 Ref: Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker. PMID: 26037168 Ref: Matrix metalloproteases as maestros for the dual role of LPS- and IL-10-stimulated macrophages in cancer cell behaviour. PMID: 26043921 Ref: Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. PMID: 26044119 Ref: Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations. PMID: 26045797 Ref: ADRM1-amplified metastasis gene in gastric cancer. PMID: 26052681 Ref: Quantitative proteomic analysis of paired colorectal cancer and non-tumorigenic tissues reveals signature proteins and perturbed pathways involved in CRC progression and metastasis. PMID: 26054784 Ref: Positive feedback between oncogenic KRAS and HIF-1alpha confers drug resistance in colorectal cancer. PMID: 26060408 Ref: The Tumor Suppressive Effects of HPP1 Are Mediated Through JAK-STAT-Interferon Signaling Pathways. PMID: 26061044 Ref: MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer. PMID: 26064956 Ref: The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors. PMID: 26066903 Ref: Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. PMID: 26071484 Ref: Different treatment strategies and molecular features between right-sided and left-sided colon cancers. PMID: 26074686 Ref: Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population. PMID: 26077004 Ref: Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. PMID: 26077270 Ref: The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma. PMID: 26077911 Ref: The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order. PMID: 26081767 Ref: In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation. PMID: 26085185 Ref: The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. PMID: 26086204 Ref: First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. PMID: 26088456 Ref: EGFR and beta1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion. PMID: 26096850 Ref: Aspirin Prevents Colorectal Cancer by Normalizing EGFR Expression. PMID: 26097892 Ref: MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. PMID: 26107137 Ref: Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells. PMID: 26107817 Ref: EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. PMID: 26110767 Ref: Current controversies in the management of metastatic colorectal cancer. PMID: 26113053 Ref: A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. PMID: 26137537 Ref: Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. PMID: 26137573 Ref: Rectal and colon cancer: Not just a different anatomic site. PMID: 26145760 Ref: Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. PMID: 26149458 Ref: Combinational treatment with microRNA133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR. PMID: 26151111 Ref: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. PMID: 26151329 Ref: Cortactin promotes colon cancer progression by regulating ERK pathway. PMID: 26151562 Ref: LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer. PMID: 26159916 Ref: Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials. PMID: 26160607 Ref: The Hippo pathway in colorectal cancer. PMID: 26160682 Ref: ErbB-3 activation by NRG-1beta sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). PMID: 26160848 Ref: Cost Considerations in the Evaluation and Treatment of Colorectal Cancer. PMID: 26162432 Ref: Morphological aspects of the hepatic response to neoadjuvant therapy. PMID: 26163186 Ref: Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples. PMID: 26163758 Ref: EGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging. PMID: 26181290 Ref: The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. PMID: 26199571 Ref: Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. PMID: 26206254 Ref: Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. PMID: 26206335 Ref: BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. PMID: 26208524 Ref: HIF-1alpha in colorectal carcinoma: review of the literature. PMID: 26214618 Ref: Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique. PMID: 26220423 Ref: Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. PMID: 26226847 Ref: Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach. PMID: 26227479 Ref: Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. PMID: 26238079 Ref: Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. PMID: 26242620 Ref: ERBB2 emerges as a new target for colorectal cancer. PMID: 26243861 Ref: HER2 activating mutations are targets for colorectal cancer treatment. PMID: 26243863 Ref: Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. PMID: 26244165 Ref: Can the histological type of colorectal cancer determine the carcinogenesis pathway? PMID: 26247523 Ref: Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array. PMID: 26258407 Ref: SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. PMID: 26258891 Ref: Mucinous Colorectal Adenocarcinoma: Influence of EGFR and E-Cadherin Expression on Clinicopathologic Features and Prognosis. PMID: 26262813 Ref: ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. PMID: 26267535 Ref: YES oncogenic activity is specified by its SH4 domain and regulates RAS/MAPK signaling in colon carcinoma cells. PMID: 26269757 Ref: CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice. PMID: 26275951 Ref: [Clinically relevant, gender-specific differences in colorectal carcinoma (CRC)]. PMID: 26284326 Ref: Sulfiredoxin Promotes Colorectal Cancer Cell Invasion and Metastasis through a Novel Mechanism of Enhancing EGFR Signaling. PMID: 26290602 Ref: [Colorectal cancer biology]. PMID: 26298904 Ref: [Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients]. PMID: 26299862 Ref: Rhomboid domain containing 1 promotes colorectal cancer growth through activation of the EGFR signalling pathway. PMID: 26300397 Ref: 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. PMID: 26309164 Ref: KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity. PMID: 26318594 Ref: Probing a 3,4'-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway. PMID: 26318998 Ref: Isolation and characterization of circulating micro(nano)vesicles in the plasma of colorectal cancer patients and their interactions with tumor cells. PMID: 26324403 Ref: Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. PMID: 26327923 Ref: Correlation study of Bcl-2, B7-H1, EGFR, VEGF and colorectal cancer. PMID: 26328258 Ref: The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. PMID: 26335936 Ref: Renal toxicity of anticancer agents targeting HER2 and EGFR. PMID: 26341657 Ref: Stiff substrates increase YAP-signaling-mediated matrix metalloproteinase-7 expression. PMID: 26344692 Ref: Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. PMID: 26347132 Ref: A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. PMID: 26358176 Ref: PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. PMID: 26365186 Ref: Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers. PMID: 26366557 Ref: New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia. PMID: 26369679 Ref: Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. PMID: 26372697 Ref: First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. PMID: 26374340 Ref: Maintenance therapy for colorectal cancer: which regimen and which patients? PMID: 26377935 Ref: Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. PMID: 26386973 Ref: Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. PMID: 26392303 Ref: Harvesting (67)Cu from the Collection of a Secondary Beam Cocktail at the National Superconducting Cyclotron Laboratory. PMID: 26403524 Ref: The genomic landscape of response to EGFR blockade in colorectal cancer. PMID: 26416732 Ref: Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. PMID: 26418718 Ref: DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. PMID: 26426205 Ref: Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. PMID: 26427914 Ref: Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics. PMID: 26435479 Ref: MTHFR C677T Polymorphism is Associated with Tumor Response to Preoperative Chemoradiotherapy: A Result Based on Previous Reports. PMID: 26456456 Ref: Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. PMID: 26460303 Ref: [Effect and mechanism of EGFR expression in macrophages on the anti-cancer effect of berberine on colorectal cancer]. PMID: 26463023 Ref: Optimizing Anti-EGFR Therapy in Colorectal Cancer. PMID: 26463710 Ref: Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. PMID: 26468449 Ref: Surgical Specimens of Colorectal Cancer Fixed with PAXgene Tissue System Preserve High-Quality RNA. PMID: 26484572 Ref: Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway. PMID: 26491668 Ref: Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer. PMID: 26503053 Ref: Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients. PMID: 26504047 Ref: Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. PMID: 26508446 Ref: Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. PMID: 26508880 Ref: A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations. PMID: 26512781 Ref: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. PMID: 26517691 Ref: Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. PMID: 26542452 Ref: Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. PMID: 26553611 Ref: Cellular Uptake and Cytotoxic Effect of Epidermal Growth Factor Receptor Targeted and Plitidepsin Loaded Co-Polymeric Polymersomes on Colorectal Cancer Cell Lines. PMID: 26554161 Ref: The role of Reg IV in colorectal cancer, as a potential therapeutic target. PMID: 26557771 Ref: Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy. PMID: 26569228 Ref: Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer. PMID: 26569500 Ref: Old dog, new tricks: extracellular domain arginine methylation regulates EGFR function. PMID: 26571394 Ref: PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. PMID: 26571401 Ref: Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. PMID: 26572750 Ref: Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines. PMID: 26581653 Ref: Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma. PMID: 26586952 Ref: [Colorectal cancer: ten years of illusion of progress but advances are on the horizon]. PMID: 26591311 Ref: [Companion Diagnostics Sub-Section of Anatomic Pathology Department in a Mid-Sized General Hospital: Start Up and Maintenance]. PMID: 26591440 Ref: Overcoming Resistance to Targeted Therapies in Cancer. PMID: 26615134 Ref: BRAF in metastatic colorectal cancer: the future starts now. PMID: 26615988 Ref: Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. PMID: 26623049 Ref: Targeting Cathepsin B for Cancer Therapies. PMID: 26623174 Ref: Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors. PMID: 26673922 Ref: Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. PMID: 26673925 Ref: MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. PMID: 26677401 Ref: Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers. PMID: 26678268 Ref: [Alternative Splicing Detection as a Biomarker for Cancer Diagnosis: A Novel Progressive Mechanism of Acute Lymphoblastic Leukemia with Alternative Splicing as a Biomarker Candidate]. PMID: 26731899 Ref: Epidermal Growth Factor Receptor Inconsistency by Immunohistochemistry Method Using Different Monoclonal Antibodies in Colorectal Cancer Patients. PMID: 26731987 Ref: Guanylate-binding protein 1 (GBP1) promotes lymph node metastasis in human esophageal squamous cell carcinoma. PMID: 26760981 Ref: MANAGEMENT OF METASTATIC COLORECTAL CANCER: Current Treatments and New Therapies. PMID: 26821406 Ref: Multiple pathways regulate Cten in colorectal cancer without a Tensin switch. PMID: 26852686 Ref: [Companion Diagnostics for Solid Tumors]. PMID: 26995877 Ref: Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. PMID: 27081524 Ref: BRAF inhibitors in colorectal cancer: Toward a differentiation therapy? PMID: 27308494 |
Ref: Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid. PMID: 25352398 Ref: Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. PMID: 25761479 Ref: Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. PMID: 26001389 Ref: Pulmonary enteric adenocarcinoma. PMID: 26139021 Ref: Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines. PMID: 26183715 Ref: Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer. PMID: 26281864 Ref: Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. PMID: 26364891 Ref: Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells. PMID: 26386720 Ref: Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. PMID: 26437179 Ref: Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. PMID: 26438111 Ref: Potent anti-tumor effects of EGFR-targeted hybrid peptide on mice bearing liver metastases. PMID: 26467564 Ref: Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression. PMID: 26496897 Ref: A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9. PMID: 26497206 Ref: Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy procedure (CRS PMID: 26518392 Ref: The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer. PMID: 26522728 Ref: Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss. PMID: 26527747 Ref: Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. PMID: 26547136 Ref: Current and advancing treatments for metastatic colorectal cancer. PMID: 26549053 Ref: Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. PMID: 26551156 Ref: HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report. PMID: 26561417 Ref: Hydroxytyrosol, a product from olive oil, reduces colon cancer growth by enhancing epidermal growth factor receptor degradation. PMID: 26577496 Ref: KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. PMID: 26610798 Ref: Epiregulin Recognition Mechanisms by Anti-epiregulin Antibody 9E5: STRUCTURAL, FUNCTIONAL, AND MOLECULAR DYNAMICS SIMULATION ANALYSES. PMID: 26627827 Ref: Relationship between Preoperative (1)(8)F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer. PMID: 26632406 Ref: Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases. PMID: 26637197 Ref: Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. PMID: 26644315 Ref: HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. PMID: 26657506 Ref: Epidermal growth factor receptor mediated proliferation depends on increased lipid droplet density regulated via a negative regulatory loop with FOXO3/Sirtuin6. PMID: 26657850 Ref: Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. PMID: 26660078 Ref: Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing. PMID: 26661077 Ref: A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. PMID: 26666244 Ref: A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients. PMID: 26666825 Ref: Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis. PMID: 26676887 Ref: Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection. PMID: 26678613 Ref: HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. PMID: 26690310 Ref: Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro. PMID: 26708311 Ref: Epidermal growth factor receptor-targeted therapy in colorectal cancer. PMID: 26709782 Ref: Pristimerin demonstrates anticancer potential in colorectal cancer cells by inducing G1 phase arrest and apoptosis and suppressing various pro-survival signaling proteins. PMID: 26718323 Ref: Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer. PMID: 26719345 Ref: Necitumumab: First Global Approval. PMID: 26729188 Ref: Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. PMID: 26741147 Ref: A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer. PMID: 26759349 Ref: Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer. PMID: 26779809 Ref: [What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers]. PMID: 26790710 Ref: Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. PMID: 26797410 Ref: [Application of molecular diagnostic techniques in precision medicine of personalized treatment for colorectal cancer]. PMID: 26797832 Ref: Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. PMID: 26798432 Ref: EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. PMID: 26810733 Ref: Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer. PMID: 26811602 Ref: Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. PMID: 26811634 Ref: Validation of a Multiplex Allele-Specific Polymerase Chain Reaction Assay for Detection of KRAS Gene Mutations in Formalin-Fixed, Paraffin-Embedded Tissues from Colorectal Cancer Patients. PMID: 26812617 Ref: Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy. PMID: 26817995 Ref: Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? PMID: 26824184 Ref: Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. PMID: 26831715 Ref: Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications. PMID: 26842924 Ref: MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. PMID: 26843189 Ref: HER3 expression is correlated to distally located and low-grade colon cancer. PMID: 26863446 Ref: Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity. PMID: 26864072 Ref: Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. PMID: 26867820 Ref: Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. PMID: 26869800 Ref: The Report of KRAS Mutation and NRAS Wild Type in a Patient with Thyroid Metastasis from Colon Cancer: a Rare Case Report. PMID: 26870147 Ref: Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study. PMID: 26870292 Ref: Design, synthesis and molecular modeling studies of few chalcone analogues of benzimidazole for epidermal growth factor receptor inhibitor in search of useful anticancer agent. PMID: 26878127 Ref: The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. PMID: 26888827 Ref: Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. PMID: 26892442 Ref: GeneGazer: A Toolkit Integrating Two Pipelines for Personalized Profiling and Biosignature Identification. PMID: 26912804 Ref: Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. PMID: 26917275 Ref: The possibility of clinical sequencing in the management of cancer. PMID: 26917600 Ref: Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. PMID: 26925640 Ref: Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis. PMID: 26927802 Ref: Potential Therapy for Refractory Colon Cancer. PMID: 26928314 Ref: Downregulation of epidermal growth factor receptor family receptors and ligands in a mutant K-ras group of patients with colorectal cancer. PMID: 26935861 Ref: Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance. PMID: 26956206 Ref: Biomarkers in Colorectal Cancer. PMID: 26977004 Ref: The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status. PMID: 26980146 Ref: The safety of monoclonal antibodies for treatment of colorectal cancer. PMID: 26982510 Ref: XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer. PMID: 26984378 Ref: Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer. PMID: 26984642 Ref: Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure. PMID: 26985396 Ref: BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. PMID: 26991109 Ref: A case of psoriasis pustolosa palmaris induced by cetuximab. PMID: 26994052 Ref: KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer. PMID: 27004155 Ref: RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. PMID: 27004837 Ref: Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand? PMID: 27006256 Ref: Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. PMID: 27017409 Ref: Synergistic inhibitory effect of cetuximab and tectochrysin on human colon cancer cell growth via inhibition of EGFR signal. PMID: 27025376 Ref: Comparison of anti-inflammatory mechanisms of mango (Mangifera Indica L.) and pomegranate (Punica Granatum L.) in a preclinical model of colitis. PMID: 27028006 Ref: What is the Current Role of Immunotherapy for Colon Cancer? PMID: 27028968 Ref: Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. PMID: 27034809 Ref: Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients. PMID: 27039744 Ref: KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients. PMID: 27043547 Ref: Clinical value of intratumoral metabolic heterogeneity in [18F]FDG PET/CT for prediction of recurrence in patients with locally advanced colorectal cancer. PMID: 27045576 Ref: Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. PMID: 27050148 Ref: Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. PMID: 27055395 Ref: A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer. PMID: 27057810 Ref: Detection of EGFR expression in patients with colorectal cancer and the therapeutic effect of cetuximab. PMID: 27061536 Ref: Multiple differential expression networks identify key genes in rectal cancer. PMID: 27062700 Ref: Heterogeneity of KRAS Mutation Status in Rectal Cancer. PMID: 27064574 Ref: [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer]. PMID: 27067688 Ref: [A Case of an Unresectable Locally Advanced Rectal Cancer with Surrounding Organ Invasion Successfully Resected after Chemotherapy with mFOLFOX6 plus Cetuximab]. PMID: 27067860 Ref: Rapid and Specific Screening Assay for KRAS Oncogene Mutation by a Novel Gene Amplification Method. PMID: 27069133 Ref: Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells. PMID: 27074568 Ref: Prognostic impact of mutation profiling in patients with stage II and III colon cancer. PMID: 27074743 Ref: Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer. PMID: 27076760 Ref: Comparative analysis of copy number variations in ulcerative colitis associated and sporadic colorectal neoplasia. PMID: 27080994 Ref: Computer-aided design, synthesis, and biological evaluation of new indole-2-carboxamide derivatives as PI3Kalpha/EGFR inhibitors. PMID: 27084677 Ref: Deoxycholic acid mediates non-canonical EGFR-MAPK activation through the induction of calcium signaling in colon cancer cells. PMID: 27086143 Ref: Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells. PMID: 27090874 Ref: Ethanolic Extract of Bark from Salix aegyptiaca Ameliorates 1,2-dimethylhydrazine-induced Colon Carcinogenesis in Mice by Reducing Oxidative Stress. PMID: 27093594 Ref: miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling. PMID: 27095166 Ref: Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. PMID: 27099521 Ref: Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors. PMID: 27101000 Ref: SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline. PMID: 27102434 Ref: Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy. PMID: 27107100 Ref: Pinin facilitated proliferation and metastasis of colorectal cancer through activating EGFR/ERK signaling pathway. PMID: 27107420 Ref: Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer. PMID: 27116474 Ref: Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. PMID: 27121052 Ref: The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. PMID: 27135741 Ref: (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. PMID: 27146067 Ref: Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples. PMID: 27146902 Ref: Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor. PMID: 27149134 Ref: Colorectal cancer cells are resistant to anti-EGFR monoclonal antibody through adapted autophagy. PMID: 27158405 Ref: Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. PMID: 27178450 Ref: Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. PMID: 27179112 Ref: Concordance of KRAS mutation status between luminal and peripheral regions of primary colorectal cancer. A laser-capture microdissection-based study. PMID: 27179269 Ref: The Discovery and Characterization of K-756, a Novel Wnt/beta-Catenin Pathway Inhibitor Targeting Tankyrase. PMID: 27196752 Ref: Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse. PMID: 27200415 Ref: Hsp70 exerts oncogenic activity in the Apc mutant Min mouse model. PMID: 27207671 Ref: [A Case of Advanced Colon Cancer with Long-Term and Re-Administration of Regorafenib]. PMID: 27210098 Ref: Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases. PMID: 27218826 Ref: SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway. PMID: 27220321 Ref: Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran. PMID: 27221845 Ref: ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. PMID: 27246726 Ref: Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter. PMID: 27270421 Ref: Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. PMID: 27270901 Ref: Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. PMID: 27272216 Ref: Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers. PMID: 27275783 Ref: Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. PMID: 27283768 Ref: Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis. PMID: 27284437 Ref: PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study. PMID: 27296289 Ref: Hsa-miR-875-5p exerts tumor suppressor function through down-regulation of EGFR in colorectal carcinoma (CRC). PMID: 27302926 Ref: Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery. PMID: 27311775 Ref: Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. PMID: 27312529 Ref: Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PMID: 27314237 Ref: Construction of a protein-protein interaction network of Wilms' tumor and pathway prediction of molecular complexes. PMID: 27323086 Ref: MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. PMID: 27325282 Ref: FAT1: a potential target for monoclonal antibody therapy in colon cancer. PMID: 27328312 Ref: Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. PMID: 27332557 Ref: Diagnostic RAS mutation analysis by polymerase chain reaction (PCR). PMID: 27335808 Ref: Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. PMID: 27340349 Ref: Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment. PMID: 27341591 Ref: Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. PMID: 27342247 Ref: Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients. PMID: 27344184 Ref: Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting. PMID: 27345057 Ref: Nuclear Y-Box-binding Protein-1 Expression Predicts Poor Clinical Outcome in Stage III Colorectal Cancer. PMID: 27354655 Ref: Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody. PMID: 27364553 Ref: Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer. PMID: 27373506 Ref: Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. PMID: 27382031 Ref: DNA methylation based biomarkers in colorectal cancer: A systematic review. PMID: 27385266 Ref: In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity. PMID: 27392434 Ref: Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma. PMID: 27399917 Ref: Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method. PMID: 27405731 Ref: Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature. PMID: 27409671 Ref: Determination of a novel B-Raf(V600E) and EGFR dual inhibitor in rat plasma by HPLC-MS/MS and its application in a pharmacokinetic study. PMID: 27423011 Ref: CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. PMID: 27435270 Ref: Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. PMID: 27446446 Ref: Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. PMID: 27448974 Ref: GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer. PMID: 27460045 Ref: Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context. PMID: 27461835 Ref: Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). PMID: 27465221 Ref: IGF1R and c-met as therapeutic targets for colorectal cancer. PMID: 27470393 Ref: A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing. PMID: 27485514 Ref: Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations. PMID: 27499925 Ref: TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. PMID: 27509063 Ref: Molecular Evaluation of Colorectal Adenocarcinoma: Current Practice and Emerging Concepts. PMID: 27523970 Ref: Overexpression of CHKA contributes to tumor progression and metastasis and predicts poor prognosis in colorectal carcinoma. PMID: 27556502 Ref: High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer. PMID: 27562229 Ref: Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing. PMID: 27568332 Ref: Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. PMID: 27569653 Ref: Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. PMID: 27570430 Ref: Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. PMID: 27578253 Ref: Correlations between EGFR gene polymorphisms and pleural metastasis of lung adenocarcinoma. PMID: 27601918 Ref: Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model. PMID: 27602116 Ref: Targeting H19 by lentivirus-mediated RNA interference increases A549 cell migration and invasion. PMID: 27607135 Ref: Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer. PMID: 27610130 Ref: Multisciplinary management of patients with liver metastasis from colorectal cancer. PMID: 27621569 Ref: Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer. PMID: 27626684 Ref: The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment. PMID: 27630277 Ref: Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR. PMID: 27632281 Ref: Plant Phenolics Ferulic Acid and P-Coumaric Acid Inhibit Colorectal Cancer Cell Proliferation through EGFR Down-Regulation. PMID: 27644655 Ref: A perspective on anti-EGFR therapies targeting triple-negative breast cancer. PMID: 27648353 Ref: Identifying N-Glycan Biomarkers in Colorectal Cancer by Mass Spectrometry. PMID: 27653471 Ref: Genomic characterization of liver metastases from colorectal cancer patients. PMID: 27662660 Ref: Role of targeted therapy in metastatic colorectal cancer. PMID: 27672422 Ref: Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. PMID: 27682134 Ref: Multi-Center Evaluation of the Fully Automated PCR-Based Idylla KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer. PMID: 27685259 Ref: FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. PMID: 27685445 Ref: Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system in human gastric cancer cells. PMID: 27685907 Ref: Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody. PMID: 27688901 Ref: Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. PMID: 27699178 Ref: Asporin enhances colorectal cancer metastasis through activating the EGFR/src/cortactin signaling pathway. PMID: 27705916 Ref: A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors. PMID: 27708224 Ref: Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer. PMID: 27709113 Ref: Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. PMID: 27721235 Ref: Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. PMID: 27729020 Ref: Unresectable liver metastases in colorectal cancer: review of current strategies. PMID: 27733753 Ref: Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. PMID: 27737711 Ref: The prospect of patritumab for treating non-small cell lung cancer. PMID: 27744717 Ref: RAS and BRAF in metastatic colorectal cancer management. PMID: 27747083 Ref: Beyond RAS and BRAF: a target rich disease that is ripe for picking. PMID: 27747084 Ref: Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. PMID: 27756306 Ref: Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. PMID: 27756406 Ref: Triple Therapy Improves Colorectal Cancer Response. PMID: 27770002 Ref: Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. PMID: 27777877 Ref: [Pancreatic acinar neoplasms : Comparative molecular characterization]. PMID: 27807633 Ref: FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc. PMID: 27825133 Ref: Noscapine targets EGFR(p-Tyr1068) to suppress the proliferation and invasion of MG63 cells. PMID: 27830833 Ref: Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to Fluorouracil-induced apoptosis by affecting autophagy. PMID: 27833077 Ref: Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia. PMID: 27837635 Ref: MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer. PMID: 27842308 Ref: Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. PMID: 27843629 Ref: Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. PMID: 27843640 Ref: A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers. PMID: 27845412 Ref: Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. PMID: 27845624 Ref: Nox1 promotes colon cancer cell metastasis via activation of the ADAM17 pathway. PMID: 27874952 Ref: Targeted Therapy of Colorectal Cancer. PMID: 27889786 Ref: Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) and Microsatellite Instability in Patients with Colorectal Cancer and Its Clinical Features. PMID: 27889996 Ref: [New Classification for Advanced Colorectal Cancer Using CancerPlex(R)Genomic Tests]. PMID: 27899776 Ref: Bile acid: a potential inducer of colon cancer stem cells. PMID: 27908290 Ref: High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. PMID: 27916952 Ref: Mechanisms underlying (18)F-fluorodeoxyglucose accumulation in colorectal cancer. PMID: 27928469 Ref: Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. PMID: 27929064 Ref: Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases. PMID: 27995091 Ref: Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers. PMID: 27999270 Ref: [Target Therapy in Unresectable or Metastatic Colorectal Cancer]. PMID: 28025473 Ref: Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery. PMID: 28028983 Ref: [A Case of Metastatic Colon Cancer Dramatically Affected by Anti-EGFR Antibody Therapy]. PMID: 28133136 Ref: [A Case of Metastatic Colorectal Cancer with HER2 Overexpression/Amplification]. PMID: 28133304 Ref: Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. PMID: 28356789 |
Ref: Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. PMID: 26461472 Ref: Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. PMID: 26799287 Ref: Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. PMID: 26916220 Ref: Inhibition of NF-kappaB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38. PMID: 27060453 Ref: BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. PMID: 27354468 Ref: Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. PMID: 27401248 Ref: ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet-associated Colon Cancer. PMID: 27489286 Ref: Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. PMID: 27600383 Ref: Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway. PMID: 27603596 Ref: KITENIN functions as a fine regulator of ErbB4 expression level in colorectal cancer via protection of ErbB4 from E3-ligase Nrdp1-mediated degradation. PMID: 27648936 Ref: Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. PMID: 27750395 Ref: Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. PMID: 27771609 Ref: A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. PMID: 27853996 Ref: miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer. PMID: 27878272 Ref: EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. PMID: 27879995 Ref: Hierarchical investigating the predictive value of p53, COX2, EGFR, nm23 in the post-operative patients with colorectal carcinoma. PMID: 27888614 Ref: In-silico and in-vitro anti-cancer potential of a curcumin analogue (1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione. PMID: 27889234 Ref: Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis. PMID: 27897268 Ref: Cortactin promotes colorectal cancer cell proliferation by activating the EGFR-MAPK pathway. PMID: 27903975 Ref: The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. PMID: 27907852 Ref: From tumour heterogeneity to advances in precision treatment of colorectal cancer. PMID: 27922044 Ref: FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway. PMID: 27926503 Ref: Pro-metastatic intracellular signaling of the elaidic trans fatty acid. PMID: 27959384 Ref: KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies. PMID: 27965461 Ref: High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. PMID: 28000889 Ref: Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. PMID: 28002810 Ref: High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. PMID: 28005260 Ref: Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer. PMID: 28006840 Ref: Interacting post-muscarinic receptor signaling pathways potentiate matrix metalloproteinase-1 expression and invasion of human colon cancer cells. PMID: 28008134 Ref: EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. PMID: 28025786 Ref: Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. PMID: 28031175 Ref: Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. PMID: 28032592 Ref: Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. PMID: 28055269 Ref: Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. PMID: 28058585 Ref: Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. PMID: 28068936 Ref: Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. PMID: 28073102 Ref: Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells. PMID: 28086832 Ref: Medical Oncologists' Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care. PMID: 28095174 Ref: The Role of Liquid Based Cytology and Ancillary Techniques in the Peritoneal Washing Analysis: Our Institutional Experience. PMID: 28099523 Ref: [Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer]. PMID: 28105616 Ref: Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. PMID: 28106345 Ref: Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. PMID: 28106826 Ref: Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis. PMID: 28110551 Ref: Current Status and Perspectives Regarding the Therapeutic Potential of Targeting EGFR Pathway by Curcumin in Lung Cancer. PMID: 28117012 Ref: The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives. PMID: 28120720 Ref: Low Incidence along with Low mRNA Levels of EGFR(vIII) in Prostate and Colorectal Cancers Compared to Glioblastoma. PMID: 28123609 Ref: Identification of terpenoids from Rubus corchorifolius L. f. leaves and their anti-proliferative effects on human cancer cells. PMID: 28134947 Ref: Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers. PMID: 28137239 Ref: Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. PMID: 28138221 Ref: Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. PMID: 28165284 Ref: Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. PMID: 28165299 Ref: Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor. PMID: 28166195 Ref: Novel ent-Kaurane Diterpenoid from Rubus corchorifolius L. f. Inhibits Human Colon Cancer Cell Growth via Inducing Cell Cycle Arrest and Apoptosis. PMID: 28169543 Ref: Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. PMID: 28170370 Ref: Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. PMID: 28173629 Ref: Circular RNA ciRS-7-A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer. PMID: 28174233 Ref: Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF. PMID: 28182330 Ref: Gene expression changes in colon tissues from colorectal cancer patients following the intake of an ellagitannin-containing pomegranate extract: a randomized clinical trial. PMID: 28183047 Ref: Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. PMID: 28185757 Ref: Prophylactic vaccination targeting ERBB3 decreases polyp burden in a mouse model of human colorectal cancer. PMID: 28197371 Ref: ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. PMID: 28199979 Ref: In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. PMID: 28220124 Ref: Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway. PMID: 28230863 Ref: Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer. PMID: 28232873 Ref: Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform. PMID: 28243320 Ref: [Does the sidedness determine the first line treatment of irresectable metastatic colorectal cancer?] PMID: 28245681 Ref: Evaluation of 6-chloro-N-[3,4-disubstituted-1,3-thiazol-2(3H)-ylidene]-1,3-benzothiazol-2-amine Using Drug Design Concept for Their Targeted Activity Against Colon Cancer Cell Lines HCT-116, HCT15, and HT29. PMID: 28259893 Ref: Long-term survival after a favorable response to anti-EGFR antibody plus chemotherapy to treat bone marrow metastasis: a case report of KRAS-wildtype rectal cancer. PMID: 28260928 Ref: A novel KRAS gene mutation report in sporadic colorectal cancer, from Northwest of Iran. PMID: 28265402 Ref: Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives. PMID: 28270084 Ref: Genetic dissection of colorectal cancer progression by orthotopic transplantation of engineered cancer organoids. PMID: 28270604 Ref: Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. PMID: 28280091 Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. PMID: 28280620 Ref: Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. PMID: 28283541 Ref: In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. PMID: 28301591 Ref: Intratumorous heterogeneity for RAS mutations in a treatment-naive colorectal tumour. PMID: 28314739 Ref: Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer. PMID: 28320945 Ref: Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer. PMID: 28323034 Ref: EGFR gene regulation in colorectal cancer cells by garlic phytocompounds with special emphasis on S-Allyl-L-Cysteine Sulfoxide. PMID: 28349439 Ref: HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. PMID: 28363756 Ref: A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. PMID: 28363909 Ref: MicroR-545 mediates colorectal cancer cells proliferation through up-regulating epidermal growth factor receptor expression in HOTAIR long non-coding RNA dependent. PMID: 28364379 Ref: Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1. PMID: 28366103 Ref: Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. PMID: 28382467 Ref: Using circulating cell-free DNA to monitor personalized cancer therapy. PMID: 28393575 Ref: Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping. PMID: 28398227 Ref: EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. PMID: 28400195 Ref: Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors. PMID: 28403349 Ref: Multi-factorial modulation of colorectal carcinoma cells motility - partial coordination by the tetraspanin Co-029/tspan8. PMID: 28418857 Ref: Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. PMID: 28419195 Ref: Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer. PMID: 28422714 Ref: First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. PMID: 28422758 Ref: The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-beta- catenin signaling axis. PMID: 28423516 Ref: Patient considerations in metastatic colorectal cancer - role of panitumumab. PMID: 28435294 Ref: Silencing CDR1as inhibits colorectal cancer progression through regulating microRNA-7. PMID: 28435295 Ref: Rational design of non-resistant targeted cancer therapies. PMID: 28436422 Ref: Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and beta-catenin immunostaining for differentiation from metastatic colorectal carcinoma. PMID: 28438615 Ref: EGFR-targeted micelles containing near-infrared dye for enhanced photothermal therapy in colorectal cancer. PMID: 28445743 Ref: RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer. PMID: 28445956 Ref: Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. PMID: 28446505 Ref: Risk factors for brain metastases in patients with metastatic colorectal cancer. PMID: 28447565 Ref: Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. PMID: 28451421 Ref: Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. PMID: 28473715 Ref: Up-regulation of SLC9A9 Promotes Cancer Progression and Is Involved in Poor Prognosis in Colorectal Cancer. PMID: 28476790 Ref: Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine. PMID: 28486761 Ref: Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. PMID: 28507280 Ref: CPEB4 immunohistochemical expression is associated to prognosis in stage IV colorectal carcinoma. PMID: 28551384 Ref: Influence of mucinous and necrotic tissue in colorectal cancer samples on KRAS mutation analysis. PMID: 28551386 Ref: EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. PMID: 28560458 Ref: Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. PMID: 28561063 Ref: Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients. PMID: 28570747 Ref: Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity. PMID: 28580315 Ref: The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. PMID: 28583095 Ref: Libidibia ferrea presents antiproliferative, apoptotic and antioxidant effects in a colorectal cancer cell line. PMID: 28586741 Ref: The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer. PMID: 28591157 Ref: BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. PMID: 28591715 Ref: A Combined ULBP2 and SEMA5A Expression Signature as a Prognostic and Predictive Biomarker for Colon Cancer. PMID: 28607584 Ref: A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers. PMID: 28611106 Ref: Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations. PMID: 28611205 Ref: Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. PMID: 28618197 Ref: Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. PMID: 28618430 Ref: The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. PMID: 28632725 Ref: Nuclear Expression of GS28 Protein: A Novel Biomarker that Predicts Prognosis in Colorectal Cancers. PMID: 28638266 Ref: Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits. PMID: 28639239 Ref: Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model. PMID: 28649441 Ref: RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016). PMID: 28653203 Ref: Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? PMID: 28665451 Ref: MicroRNA 375 regulates proliferation and migration of colon cancer cells by suppressing the CTGF-EGFR signaling pathway. PMID: 28670764 Ref: The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economi PMID: 28682222 Ref: Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. PMID: 28685087 Ref: Systemic analysis of different colorectal cancer cell lines and TCGA datasets identified IGF-1R/EGFR-PPAR-CASPASE axis as important indicator for radiotherapy sensitivity. PMID: 28687332 Ref: Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. PMID: 28695301 Ref: EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer. PMID: 28698359 Ref: Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer. PMID: 28714940 Ref: Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies. PMID: 28718672 Ref: Morphology with immunohistochemical and genetic profiling of high-grade neuroendocrine carcinoma of colon - a case report with review of literature. PMID: 28730258 Ref: Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells. PMID: 28731466 Ref: Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. PMID: 28736627 Ref: Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. PMID: 28736628 Ref: Primary and acquired resistance to biologic therapies in gastrointestinal cancers. PMID: 28736637 Ref: A Novel Role for MiR-520a-3p in Regulating EGFR Expression in Colorectal Cancer. PMID: 28738328 Ref: Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis. PMID: 28739265 Ref: Berberine inhibits colitis-associated tumorigenesis via suppressing inflammatory responses and the consequent EGFR signaling-involved tumor cell growth. PMID: 28759012 Ref: Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma. PMID: 28759045 Ref: TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. PMID: 28760399 Ref: Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer. PMID: 28764718 Ref: Aberrantly methylated-differentially expressed genes and pathways in colorectal cancer. PMID: 28794688 Ref: Recent developments in the treatment of metastatic colorectal cancer. PMID: 28794806 Ref: Characterisation of tumour-derived microvesicles in cancer patients' blood and correlation with clinical outcome. PMID: 28804596 Ref: Mesua ferrea stem bark extract induces apoptosis and inhibits metastasis in human colorectal carcinoma HCT 116 cells, through modulation of multiple cell signalling pathways. PMID: 28807224 Ref: MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. PMID: 28819429 Ref: A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors. PMID: 28819451 Ref: Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death. PMID: 28823963 Ref: Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition. PMID: 28852020 Ref: Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis. PMID: 28858102 Ref: Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. PMID: 28859058 Ref: Potential Application of Eicosapentaenoic Acid Monoacylglyceride in the Management of Colorectal Cancer. PMID: 28869531 Ref: Ex Vivo and In Vivo Noninvasive Imaging of Epidermal Growth Factor Receptor Inhibition on Colon Tumorigenesis Using Activatable Near-Infrared Fluorescent Probes. PMID: 28884622 Ref: Research progress on genetic heterogeneity between primary and paired metastatic colorectal cancer. PMID: 28903907 Ref: The lauric acid-activated signaling prompts apoptosis in cancer cells. PMID: 28924490 Ref: The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. PMID: 28928860 Ref: EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features. PMID: 28936923 Ref: Predictive clinical model of tumor response after chemoradiation in rectal cancer. PMID: 28938543 Ref: Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. PMID: 28951457 Ref: Multiple Gene-Environment Interactions on the Angiogenesis Gene-Pathway Impact Rectal Cancer Risk and Survival. PMID: 28956832 Ref: High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer. PMID: 28972570 Ref: Hijiki and sodium arsenite stimulate growth of human colorectal adenocarcinoma cells through ERK1/2 activation. PMID: 28974440 Ref: KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care. PMID: 28979819 Ref: Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. PMID: 28981524 Ref: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. PMID: 29024937 Ref: Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis. PMID: 29029527 Ref: lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/beta-catenin signaling. PMID: 29035371 Ref: Enhanced Specificity of BRAF V600E Genotyping Using Wild-Type Blocker Coupled with Internal Competitive Reference in a Single Tube. PMID: 29035465 Ref: PKCepsilon phosphorylates MIIP and promotes colorectal cancer metastasis through inhibition of RelA deacetylation. PMID: 29038521 Ref: [Anti-EGFR Antibody Combination Chemotherapy Was Effective against Locally Advanced Ascending Colon Cancer as Well as a Recurrent Lesion - A Case Report]. PMID: 29066705 Ref: RPN2 promotes colorectal cancer cell proliferation through modulating the glycosylation status of EGFR. PMID: 29069815 Ref: Establishing a colorectal cancer liver metastasis patient-derived tumor xenograft model for the evaluation of personalized chemotherapy. PMID: 29094026 Ref: Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients. PMID: 29100436 Ref: microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. PMID: 29115941 Ref: In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. PMID: 29125233 Ref: Rapid and accurate detection of KRAS mutations in colorectal cancers using the isothermal-based optical sensor for companion diagnostics. PMID: 29137388 Ref: PUMA mediates the anti-cancer effect of osimertinib in colon cancer cells. PMID: 29138581 Ref: HDAC-4 regulates claudin-2 expression in EGFR-ERK1/2 dependent manner to regulate colonic epithelial cell differentiation. PMID: 29152115 Ref: Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. PMID: 29156800 Ref: MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9. PMID: 29199273 Ref: KRAS biomarker testing disparities in colorectal cancer patients in New Mexico. PMID: 29202108 Ref: Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. PMID: 29212194 Ref: [Mechanism of cross talk between tissue factor/active coagulation factor VII and epidermal growth factor receptor signalings in colon cancer cells in culture]. PMID: 29263461 Ref: Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects. PMID: 29280968 Ref: AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer. PMID: 29285233 Ref: Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. PMID: 29285234 Ref: The correlations between serum amphiregulin and other clinicopathological factors in colorectal cancer. PMID: 29299357 Ref: Loss of PACS-2 delays regeneration in DSS-induced colitis but does not affect the Apc(Min) model of colorectal cancer. PMID: 29312533 Ref: Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. PMID: 29312543 Ref: Cetuximab-Associated Crescentic Diffuse Proliferative Glomerulonephritis. PMID: 29348949 Ref: Network analysis of common genes related to esophageal, gastric, and colon cancers. PMID: 29379595 Ref: EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function. PMID: 29383110 Ref: [Case Report of Long-Term Survival for Stage IV Advanced Sigmoid Colon Cancer with Para-Aortic Nodes by R0 Resection and Chemotherapy]. PMID: 29394654 |
Ref: Molecular Predictors of Response to Neoadjuvant Chemoradiation for Rectal Cancer. PMID: 27740975 Ref: Protein and glycomic plasma markers for early detection of adenoma and colon cancer. PMID: 27821646 Ref: Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort. PMID: 28044264 Ref: The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration. PMID: 28183250 Ref: Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives. PMID: 28183254 Ref: Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. PMID: 28262927 Ref: Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations. PMID: 28359236 Ref: Synthesis, Characterization of 4-Anilino-6,7-Dimethoxy Quinazoline Derivatives as Potential Anti-Angiogenic Agents. PMID: 28403784 Ref: The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. PMID: 28407239 Ref: Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials? PMID: 28432610 Ref: The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. PMID: 28643125 Ref: Ezrin Orchestrates Signal Transduction in Airway Cells. PMID: 28702704 Ref: Simvastatin enhances radiation sensitivity of colorectal cancer cells. PMID: 28916945 Ref: RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. PMID: 28950295 Ref: A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy. PMID: 28974546 Ref: Comparison of the effect of chemical composition of anthocyanin-rich plant extracts on colon cancer cell proliferation and their potential mechanism of action using in vitro, in silico, and biochemical assays. PMID: 29037704 Ref: Peptide ligands for targeting the extracellular domain of EGFR: Comparison between linear and cyclic peptides. PMID: 29052959 Ref: HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway. PMID: 29073728 Ref: Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. PMID: 29075780 Ref: Epidermal Growth Factor and Granulocyte Colony Stimulating Factor Signaling Are Synergistic for Hematopoietic Regeneration. PMID: 29086459 Ref: Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. PMID: 29129559 Ref: LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity. PMID: 29149105 Ref: MicroRNAs as novel biomarkers for colorectal cancer: New outlooks. PMID: 29156521 Ref: Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance. PMID: 29158469 Ref: Wnt/beta-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer. PMID: 29167314 Ref: Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management. PMID: 29174709 Ref: Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. PMID: 29196463 Ref: Does the Addition of Biologic Agents to Chemotherapy in Patients with Unresectable Colorectal Cancer Metastases Result in a Higher Proportion of Patients Undergoing Resection? A Systematic Review and Meta-analysis. PMID: 29204907 Ref: TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting beta-CATENIN and AKT Signaling in Colorectal Cancer. PMID: 29222171 Ref: Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. PMID: 29242316 Ref: Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. PMID: 29254887 Ref: Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. PMID: 29259073 Ref: The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review. PMID: 29279095 Ref: Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. PMID: 29301589 Ref: Genotyping of KRAS Mutational Status by the In-Check Lab-on-Chip Platform. PMID: 29304017 Ref: Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer. PMID: 29304903 Ref: Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. PMID: 29308327 Ref: BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. PMID: 29326440 Ref: Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. PMID: 29327707 Ref: RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment. PMID: 29333594 Ref: Intratumoral morphological heterogeneity can be an indicator of genetic heterogeneity in colorectal cancer. PMID: 29337243 Ref: Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. PMID: 29338072 Ref: Pretargeted Immuno-PET Based on Bioorthogonal Chemistry for Imaging EGFR Positive Colorectal Cancer. PMID: 29338219 Ref: Caveolin-1 Inhibits Proliferation, Migration, and Invasion of Human Colorectal Cancer Cells by Suppressing Phosphorylation of Epidermal Growth Factor Receptor. PMID: 29339715 Ref: Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer. PMID: 29344282 Ref: Targeting M3 Muscarinic Receptors for Colon Cancer Therapy. PMID: 29357811 Ref: Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer. PMID: 29361822 Ref: [A Case of Rectal Cancer with Multiple Endocrine Neoplasia Type 2]. PMID: 29362346 Ref: Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab. PMID: 29363109 Ref: Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer. PMID: 29367069 Ref: Panitumumab-Conjugated and Platinum-Cored pH-Sensitive Apoferritin Nanocages for Colorectal Cancer-Targeted Therapy. PMID: 29368506 Ref: A novel cell line generated using the CRISPR/Cas9 technology as universal quality control material for KRAS G12V mutation testing. PMID: 29380513 Ref: Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. PMID: 29388061 Ref: Epidermal growth factor receptor-targeted immune magnetic liposomes capture circulating colorectal tumor cells efficiently. PMID: 29391757 Ref: Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer. PMID: 29403291 Ref: The importance of EGFR as a biomarker in molecular apocrine breast cancer. PMID: 29409930 Ref: Colorectal signet ring cell carcinoma: Influence of EGFR, E-cadherin and MMP-13 expression on clinicopathological features and prognosis. PMID: 29414397 Ref: Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far? PMID: 29414818 Ref: Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF(V600E) Colorectal Cancer. PMID: 29431697 Ref: Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer. PMID: 29431699 Ref: Polyphenol extracts from dried sugarcane inhibit inflammatory mediators in an in vitro colon cancer model. PMID: 29432917 Ref: Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. PMID: 29438965 Ref: PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d. PMID: 29449544 Ref: Common Deregulation of Seven Biological Processes by MicroRNAs in Gastrointestinal Cancers. PMID: 29459716 Ref: First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. PMID: 29470838 Ref: Colorectal cancer spheroid biobanks: multi-level approaches to drug sensitivity studies. PMID: 29478126 Ref: Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold. PMID: 29482389 Ref: The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer. PMID: 29483217 Ref: [A Case of Surgery after Chemotherapy for Cecal Cancer with Onset of the Stenosis of the Colostomy]. PMID: 29483445 Ref: Clinicopathologic Significance of Intestinal-type Molecules' Expression and Different EGFR Gene Status in Pulmonary Adenocarcinoma. PMID: 29489510 Ref: Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status. PMID: 29490990 Ref: Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. PMID: 29498789 Ref: pH-Responsive Nanophotosensitizer for an Enhanced Photodynamic Therapy of Colorectal Cancer Overexpressing EGFR. PMID: 29498860 Ref: Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway. PMID: 29499765 Ref: [Relationships between the enrichment of ETBF, Fn, Hp in intestinal and colorectal cancer]. PMID: 29502368 Ref: Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: Case report and literature review. PMID: 29505011 Ref: Delineating the underlying molecular mechanisms and key genes involved in metastasis of colorectal cancer via bioinformatics analysis. PMID: 29517105 Ref: Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03). PMID: 29523646 Ref: BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. PMID: 29534162 Ref: Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells. PMID: 29541416 Ref: CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. PMID: 29549306 Ref: Cutaneous toxicities of epidermal growth factor receptor inhibitors: A prospective study in 60 Asian patients. PMID: 29549700 Ref: Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab. PMID: 29552307 Ref: Prognostic significance of EGFR and COX-2 expression in colorectal cancer and their association. A study in Greek population. PMID: 29552755 Ref: A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. PMID: 29568913 Ref: Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? PMID: 29580164 Ref: TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [(18)F] fluorodeoxyglucose ((18)F-FDG PET). PMID: 29581845 Ref: Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. PMID: 29588308 Ref: Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. PMID: 29589315 Ref: Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells. PMID: 29593231 Ref: Racial Disparities in the Molecular Landscape of Cancer. PMID: 29599344 Ref: Advances on the BRAF Front in Colorectal Cancer. PMID: 29610287 Ref: Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial. PMID: 29617381 Ref: Gambogic Acid Efficiently Kills Stem-Like Colorectal Cancer Cells by Upregulating ZFP36 Expression. PMID: 29627822 Ref: Emerging treatment options for BRAF-mutant colorectal cancer. PMID: 29628780 Ref: [Prediction of EGFR blockade responses in metastatic colorectal carcinoma]. PMID: 29631407 Ref: PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR. PMID: 29634414 Ref: Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer. PMID: 29662620 Ref: Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. PMID: 29665843 Ref: Ferric citrate and ferric EDTA but not ferrous sulfate drive amphiregulin-mediated activation of the MAP kinase ERK in gut epithelial cancer cells. PMID: 29682205 Ref: Nanoencapsulation of Novel Inhibitors of PNKP for Selective Sensitization to Ionizing Radiation and Irinotecan and Induction of Synthetic Lethality. PMID: 29688721 Ref: Selected proliferation markers correlated with dynamics of growth in colorectal cancer. PMID: 29688906 Ref: Population-based statistical inference for temporal sequence of somatic mutations in cancer genomes. PMID: 29697365 Ref: Histogram analysis of ADC in rectal cancer: associations with different histopathological findings including expression of EGFR, Hif1-alpha, VEGF, p53, PD1, and KI 67. A preliminary study. PMID: 29719621 Ref: Update on Sporadic Colorectal Cancer Genetics. PMID: 29720900 Ref: Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. PMID: 29721154 Ref: Management and grading of EGFR inhibitor-induced cutaneous toxicity. PMID: 29727211 Ref: EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes. PMID: 29740957 Ref: The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. PMID: 29745737 Ref: Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice. PMID: 29752127 Ref: Promising New Agents for Colorectal Cancer. PMID: 29752549 Ref: AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. PMID: 29755114 Ref: Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. PMID: 29755130 Ref: Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. PMID: 29755687 Ref: The evolving role of immune oncology in colorectal cancer. PMID: 29764162 Ref: Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma. PMID: 29769385 Ref: First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. PMID: 29773991 Ref: The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. PMID: 29776953 Ref: Novel insights into transcriptional dysregulation in colorectal cancer. PMID: 29788743 Ref: Colorectal Cancer: Why Does Side Matter? PMID: 29790124 Ref: Right Versus Left Colon Cancer: Resectable and Metastatic Disease. PMID: 29796712 Ref: Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab. PMID: 29802988 Ref: Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. PMID: 29846100 Ref: Angiodrastic Chemokines in Colorectal Cancer: Clinicopathological Correlations. PMID: 29850390 Ref: Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing. PMID: 29854313 Ref: Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. PMID: 29855806 Ref: Recent advances in treatment for colorectal liver metastasis. PMID: 29863162 Ref: The Effects of Different mTOR Inhibitors in EGFR Inhibitor Resistant Colon Carcinoma Cells. PMID: 29882195 Ref: Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of beta-catenin signaling. PMID: 29884842 Ref: IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells. PMID: 29886785 Ref: Mucositis with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of randomized controlled trials. PMID: 29893861 Ref: Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. PMID: 29899390 Ref: Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients. PMID: 29914973 Ref: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. PMID: 29926131 Ref: The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'. PMID: 29927360 Ref: Research progress on common adverse events caused by targeted therapy for colorectal cancer. PMID: 29928383 Ref: Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation. PMID: 29928418 Ref: Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. PMID: 29937183 Ref: Mutational status of KRAS and MMR genes in a series of colorectal carcinoma cases. PMID: 29940619 Ref: Regorafenib: A Review in Metastatic Colorectal Cancer. PMID: 29943375 Ref: Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations. PMID: 29945573 Ref: Expression of Epidermal Growth Factor Receptor in Colorectal Adenocarcinoma and its Correlation with Clinicopathological Factors. PMID: 29950257 Ref: Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation. PMID: 29964008 Ref: A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells. PMID: 29970458 Ref: Longan flower proanthocyanidins induce apoptosis in HT-29 colorectal carcinoma spheroids. PMID: 29970694 Ref: Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. PMID: 29981429 Ref: Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway. PMID: 29982425 Ref: Are ADC values of readout-segmented echo-planar diffusion-weighted imaging (RESOLVE) correlated with pathological prognostic factors in rectal adenocarcinoma? PMID: 30001205 Ref: Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. PMID: 30001368 Ref: Overexpression of the long noncoding RNA CCAT1 promotes metastasis via epithelial-to-mesenchymal transition in lung adenocarcinoma. PMID: 30008869 Ref: Targeted therapy for metastatic colorectal cancer. PMID: 30019590 Ref: Manuka honey synergistically enhances the chemopreventive effect of 5-fluorouracil on human colon cancer cells by inducing oxidative stress and apoptosis, altering metabolic phenotypes and suppressing metastasis ability. PMID: 30056083 Ref: STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening. PMID: 30068339 Ref: Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression. PMID: 30073936 Ref: Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. PMID: 30075835 Ref: Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution. PMID: 30078023 Ref: Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. PMID: 30085422 Ref: Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells. PMID: 30090970 Ref: Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. PMID: 30092682 Ref: EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer. PMID: 30096327 Ref: Precision oncology in liver cancer. PMID: 30105235 Ref: Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells. PMID: 30106444 Ref: A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition. PMID: 30112438 Ref: Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. PMID: 30116425 Ref: Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. PMID: 30118499 Ref: Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. PMID: 30122982 Ref: The tyrosine phosphorylated pro-survival form of Fas intensifies the EGF-induced signal in colorectal cancer cells through the nuclear EGFR/STAT3-mediated pathway. PMID: 30127519 Ref: Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates. PMID: 30130797 Ref: COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS. PMID: 30132520 Ref: Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC). PMID: 30150883 Ref: EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer. PMID: 30156250 Ref: Novel beta-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer. PMID: 30158525 Ref: Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. PMID: 30166348 Ref: The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. PMID: 30171333 Ref: Colonic stent-induced mechanical compression may suppress cancer cell proliferation in malignant large bowel obstruction. PMID: 30171397 Ref: Histogram Analysis of Perfusion Parameters from Dynamic Contrast-Enhanced MR Imaging with Tumor Characteristics and Therapeutic Response in Locally Advanced Rectal Cancer. PMID: 30186857 Ref: Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation. PMID: 30187356 Ref: PDEdelta inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. PMID: 30194764 Ref: Neratinib augments the lethality of [regorafenib + sildenafil]. PMID: 30203445 Ref: Extracellular galectin-3 facilitates colon cancer cell migration and is related to the epidermal growth factor receptor. PMID: 30210679 Ref: Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment. PMID: 30214200 Ref: Pre-emptive skin treatments to prevent skin toxicity caused by anti-EGFR antibody: the real-world evidence in Japan. PMID: 30215532 Ref: An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review. PMID: 30218345 Ref: EGF ligand fused to truncated Pseudomonas aeruginosa exotoxin A specifically targets and inhibits EGFRpositive cancer cells. PMID: 30226622 Ref: Liquid Biopsy to Identify Actionable Genomic Alterations. PMID: 30231331 Ref: Expression of epidermal growth factor receptor (EGFR) in colorectal cancer: An immunohistochemical study. PMID: 30243897 Ref: Expression of Lrig1, a negative regulator of EGFR, is dynamically altered during different stages of gastric carcinogenesis. PMID: 30248341 Ref: Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer. PMID: 30252132 Ref: A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. PMID: 30261609 Ref: The anti-metastatic effect of ginsenoside Rb2 in colorectal cancer in an EGFR/SOX2-dependent manner. PMID: 30264477 Ref: EGFR, SMAD7, and TGFBR2 Polymorphisms Are Associated with Colorectal Cancer in Patients with Lynch Syndrome. PMID: 30275229 Ref: Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study. PMID: 30290786 Ref: ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in Early Stage Gallbladder Cancer. PMID: 30304546 Ref: RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models. PMID: 30323890 Ref: EPA significantly improves anti-EGFR targeted therapy by regulating miR-378 expression in colorectal cancer. PMID: 30333883 Ref: Circulating cell-free DNA- diagnostic and prognostic applications in personalized cancer therapy. PMID: 30335711 Ref: Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach. PMID: 30344942 Ref: Recent advances in understanding colorectal cancer. PMID: 30345013 Ref: Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. PMID: 30353488 Ref: Worst outcomes according to RAS mutation variants: an analysis in patients with metastatic colorectal adenocarcinoma. PMID: 30358195 |